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Editorial 
Family physic ian are primary health prov ider and the fir t po int of 
contac t for patients navigaling the healthcare y tern. A such, family 
medic ine is the gateway to medical care fo r most palients. Thi fi eld 
encompasses the widest cope of medical practi ce of all specialtie . Our 
rationa le in choosing family medic ine a a theme for thi i ue was thu 
based on our desire to hi ghlight the important and unique nature o f thi 
med ical fi e ld . 
The broad pectrum of family med icine allowed our contributor to choo e 
fro m a wide variety o f topics of interest, still keeping a ll arti c le ex tremely 
relevant to the field of family medic ine. With a large proportion of medical 
students choosi ng family med ic ine for the ir career paths, we are excited to 
pre ent an is ue that i intended to fo ter inte rest, di scu io n, and 
awarene s of thi s fundamental area of medicine. 
We anticipate that you will enj oy the article we have included, rangi ng 
fr m in ightful commentari e to intere ting ca e tudies to up-to-date 
guide lines and rev iews. We trust that the articles will appeal to all reader , 
regardless of your specialty intere tor fi e ld o f tudy. 
A a lways we are greatly indebted to the many individual who made thi 
is ue possible. In particular, we would like to thank our departmenta l 
editors and contributors, cover artist , faculty advisors, faculty reviewer , 
the Department of Fantily Medic ine at the Univer ity of We tern Ontario, 
CU Adverti sing, the Hippocralic Council at the University of We tern 
Ontario. Finally, we thank our dedicated readers for supporting thi i ue 
and the UWOMJ. We encourage your re ponse , comment , idea and 
questi ons regarding thi i ue at uwomj @med .uwo.ca. 
Enjoy the read! 
Your editori a l staff. 
__41 .~ HV 
Melani e Sproule Hall 
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Diagnostic Review 
Ambulatory Blood Pressure Monitoring: Indications, Usage, and Interpretation 
Jaron Chong, Meds 2010 
The di agnosis o f hypertension ha traditi onall y been limi ted to offi ce blood pre sure 
reading . The ad vent of e lectronic blood pressure monitors has prov ided additi onal 
instrument to better profil e a pati ent ' blood pressure. Ambulatory Blood Pre ure 
Monitoring (ABPM), involving a blood pre sure monitor worn continuously by a 
pati ent over a 24 to 48 hour period , prov ides the most comprehen ive profi le of a 
patient ' blood pres ure. ABPM is indicated in indi viduals with suspected White-Coat 
Hypertension or Re i tant Hypertension and is a potenti a ll y va luable diagnosis 
modality. It provides high temporal resoluti on with unbia ed reporting of blood pre ure 
to the physician. In addition, it is better able to characte ri ze nocturnal blood pre sure, 
omething not po ible with o ffi ce or home/self bl ood pre sure record ings. The 
Canadi an Hypertension Educati on Program (CHEP) has defined AB PM thresho lds of 
hyperten ion to be greater than 135/85 mmHg mean awake BP or greater than 130/80 
mmHg fo r mean 24hr BP 's. These thresholds are lower than the traditi onal o ffi ce 
thresholds of 140/90 mm.Hg. ABPM results can be used to reduce unnecessary anti -
hyperten ive therapy a we ll as modi fy dose scheduling to cover ' blind spot ' in blood 
pressure regulation. It can also provide additio nal diagnostic information regarding the 
contributing fac tors to a pati ent 's re i tant hyperten ion. For the time being, ABPM i 
only moderately cost-effecti ve under certain clinical indications and thus is unfunded by 
OHIP. Nonetheless, it remains an additional dimension to hypertension di agnosis that 
all healthcare professionals should be aware of. 
This article has been reviewed by Dr. Louise Moist. 
Introduction 
Hypertension, as defined by the Canadian Hypertension Education Program (CHEP), i considered as a 
sys tolic blood pressure (SBP) of 140nunHg or higher and a diasto lic blood pre sure (DBP) of 90mmHg or higher. 1 It 
affects 27% of the Canadian adult population between the ages of 35 and 64 .2 Hyperten ion is the most important 
ri sk factor for troke as well as the leading preceding condition to heart fa ilure. It is al o a noted ri sk factor for heart 
attacks, arteria l aneurysms, and chronic renal failure. 3 
Blood Pressure Variability 
Blood pressure doe express some normal vari ability with research by Millar-Craig et al. establi hing the 
circadian variation of blood-pressure. Blood pressure ordinaril y peak during mid-morning, is lowest at night, and 
ri e before awakening.4 25-35% of pati ents do not express a dip in blood pressure at night and are termed ' non-
dippers'. Pati ents without this dip have been a ociated with increased sympathe tic acti vity during sleep, worse 
prognosis, and eleva ted ri sk of end-organ injury such as progressive renal insufficiency.5· 6 
White-Coat Hypertension 
A clinical phenomenon, known a white-coat hypertension (W CHT), exists whereby an individual' s blood 
pres ure ri es in response to anx iety brought o n by a visit to a physic ian's offi ce. 7 A conm1on definition o f WCHT is 
a high blood pre sure (BP) in a physician' offi ce with a normal BP at rest or while ambulatory. This can e ither be 
defined in the hort-term as BP just before and during a vi it or in the long-term as the change between a daily 
average BP versus BP during a visit. 8' 9 In additi on, there should be no end-organ damage in order for WCHT to be 
d. d 10 1agnose . 
Conventional and Home/Self Blood Pressure Monitoring 
Conventional blood pressure monitoring mo t c lassically takes on the form of the mercury or aneroid 
sphygmomanometry performed in the phys ician's offi ce. 11 Collecti ve ly termed as office blood pres ure (OBP) 
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values or ca ual blood pre ure readings, they provide a snap hot o f a patient ' s blood pressure as performed by a 
trained pr fe siona l. 
In recent years , there ha been movement toward home blood pressure monitoring or self-blood pre sure 
monitorin g to erve a an adJ. unc t to offi ce bl ood pressure va lues. Fully automated e lectronic blood pres ure 
~ 12 h'l 
monitors are the most commonl y marketed for the ir ease-of-use and lack of reporting bias from the patient. W I e 
effec ti ve in some capac ities, limitations exjst in term of clinical va lidation of indi vidual devices a well a variable 
h . 13 mea urement chedules and number of recordi ng performed by l e pauent. 
Ambulatory Blood Pressure Monitoring (A BPM) 
Ambulatory Blood Pres ure Monitoring (ABPM) differs from conventional blood pre sure monitoring in 
that an e lectronic blood pre ure monitoring device i" worn continuou ly by a patient with readings taken at regular 
intervals (Figure J ; Figure 2). AB PM originally came about as a re earch tool with the fir t recorded mention o f 
such a device in 1 962 . 1 ~ · 15 T he very first study tha t e tabli shed the uperi ority of ambula tory blood pre sure 
reading ' wa performed u ing a modified version of the 1962 device by Sokolow and colleague in 1966. 16 Since 
that time, ABPMs have come into greater c linical u e and are now specificall y recommended by Canadian and 
American cardiovascular ocieti e under certain indication .1• 17 
ABPM device function by e ither direc tly li stening to and interpreting Korolkoff sounds u ing a 
rnicrophone, not unlike conventi onal blood pres ure monitoring, or thr ugh the sensa tion of vibratory signals while 
the pressure cuff infl ates. Pressure readings are u ua ll y co llected at 15 to 30 minute interval and stored on a 
computer chip for later viewing and interpretati on by the physic ian. Thi s provides the cl inician with an unbiased and 
deta iled review of the pati ent ' blood pre sure , usua lly over a 24 to 48 hour tudy period .1 
Interpretation of ABPM Results 
The interpretation o f re ults from ambulatory blood pre ure measurement i lightly different from 
traditi onal o ffi ce bl ood pre ure values. According to the 2007 Canad ian Hyperten ion Education Program (CHEP) 
guide line , a di agnosis o f hypertension can be made fro m ambulatory bl ood pre sure monitoring "if the mean awake 
SBP [Sy tolic Blood Pressure] is 135 mm.Hg or hjgher or the DBP [Di asto lic Blood Pre ure] i 85 mmH.g DBP or 
higher". ' An alternate determjnati on of hyperten ion can be made if the mean 24 hour blood pre sure is "130 mm.Hg 
or higher or the DBP i 80mm.Hg or higher" .1 (Figure 3) O f note i that the e threshold are lightly lower than the 
common 140/90 mJnJ-I.g traditi onally set for offi ce blood pressure .17' 19 Thi i to be expec ted given the repeated 
averaged measurements and the rrunirru zati on o f any potenti al White- oat effect. 
Clinical Indications for ABPM 
Given the additional costs incurred in utili zing ABPM, re earchers and clinician have devised specific 
indicati n. for its utili zati n. The mo t often c ited indication i uspic i n of white-coat hypertension. Individuals 
with ambi guous hyperten ion (i.e . nom1otensive home bl ood pressure reading and hyperten ive office blood 
pressure readings) can also be betler managed with ABPM data . There are e timate that between 20 to 30 percent 
of indi viduals found to be hypertensive in a phy ic ian 's o ffi ce are normoten ive at o ther time .20 By recognizing 
these indi viduals as norm ten ive r pre-hypertensive, a reducti on in antihypertensive medication side effect and 
18 21 , , 
excess costs can be reali zed . · 
Another candidate for ABPM is res istant hyperten ion, when blood pressure control is not achieved despite 
adeq uate and sustained anti -hypertensive therapy. T hi typica lly pre ents a e levated offi ce bl ood pressure , normal 
home reading. , and a lack o f apparent target-organ damage.20 One etio logy of resi tant hypertension e pecia lly 
suited to 24h ambulatory monitoring is sleep apnea . Hypertensive epi odes can occur a a re ult o f apneic pells. On 
AB PM, thi would demonstrate a a lac k of a nocturnal bl ood pr · ure dip, a finding not as easily obtained with 
offi ce or home bl ood pressure monitoring.18 
Finall y, a clinical re carch progres e and ABPM usage bee me more commonpla e, we may ee the 
general u age f ABPM in a ll hypertensive pati ent . Already, there is significant ev idence that ABPM readin o-s may 
be a beuer predictor of end-organ damage, cardiovascul ar event , and morta lity than offi ce blood pre ure _2"l.. 23 As 
noc turnal bl ood pressure at o appear to play a prognostic ro le, ABPM i able to record what conventional o ffi ce 
bl ood pressure and casual home bl od pre sure rec rding do not. 24 In addition, the 24h coverage of ABPM can 
notify a physician of 'blind spots ' in hypertensive coverage, necessitating a change in anti -hypertensive medicati on 
or do. e . cheduling.25 
- 6 - UWOMJ 77(1 ) 2008 
Costs & Availability of ABPM 
For an typical physician' s office, purchasing a monitor and assoc iated software can range on average from 
$4,500 to $5 ,500 USD. 18 ABPM is not currentl y funded by OHIP and as such there i a nominal cost as oc iated with 
its c linical u age. Canadian clinics and ho pita ls typical charge a user fee of $50 to $75 CDN per ABPM study.26 In 
compari on, M edicare and Medicaid in the United Sta te has reimbursed the co t o f ABPM for pati ents wi th a 
uspec ted diagnosi of White-Coat Hypertension.10 
There have been mixed result regarding the cost-effec ti venes of AB PM . The original tudy 
reconunending Medi care and Medicaid upport o f ABPM fo r suspected White-Coat Hyperten ion pati ents wa 
ba ed on the avoidance o f anti -hyperten ive drug adverse e ffect as we ll as the be tte r as essment o f cardi ova cular 
ri k that ABPM would offer for the phys ic ian.10 In support of the cos t-effecti veness of ABPM is a study by K.rako ff 
that projec t avi ng fo r the usage of AB PM where annual treatment costs total a minimum o f $300. Thi conc lusio n 
operates on the assumpti on that a fraction of pati ents diagnosed with White-Coat Hypertensio n would discontinue 
treatment. 27 In another s tudy by Rodriguez-Roca et al. , ABPM wa found to be only more cost-effecti ve than 
conventi onal blood pressure monitoring when the new treatment co t of poorl y monitored pati ents was not 
inc luded .28 
Conclusion 
Hypertension represent a significant is ue in modern healthcare with an aging populati on and ambulatory 
blood pres ure monitoring remains the most accurate diagnosti c modality avail able. While ideal to use in a ll patient 
with uspec ted hypertension, co t-effecti venes guidelines only seem to upport it u e in narrow indicati ons. In thi 
regard , Canada is s lightly behind the United States in terms o f public funding. However, in compari son with many 
other diagnosti c technologies, a ingle ambulatory blood pressure tudy is not nearly as prohibiti ve in co t. For the 
time be ing, awarene s of this technology and its appropri ate indication for use by all healthcare profe ionals i 
advi ed with ambulatory blood pressures adding another va luab le dimension to the monitoring of hypertensive 
patients. 
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Figures 
FIGURE 1: Ambulatory blood pressure monitor and cuff 
(Model 90207, SpaceLab Medical, Inc., Issaquah , Wash.)18 
FIGURE 2: Indi vidual wearing an ambulatory 
. 29 blood pressure momtor. 
FIGURE 3: Thre hold guideline for Ambu latory Blood Pre ure Monitoring (ABPM) uti lizing averaged blood 
pressure measurements over the duration of a study; SBP Systolic BP; DBP Diastolic BP. Adapted from the 
Canadian Hypertension Education Program. 1 
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Profiles 
Perspectives from a Community Family Physician: Past, Present and Future 
Alysia W. Zhou, Meds 2010 
Rural Di covery Week at the University of Western Ontari o (UWO) is a week of 
c linical exposure that provides students wi th their first in ight into community 
medicine, including family medicine (FM ). Dr. Joseph Mai i a famil y phy ician in St. 
T homa who participated in the 2007 Di scovery Week. He graduated with hi MD and 
CCFP at the UWO and is currently a partner at a large fa mil y med icine clinic in St. 
Thomas. Dr. Mai's interest in FM was not ev ident until the 4th year of hi s medical 
tudies, a fter which hi residency experience further reinforced hi s enj oyme nt of FM . 
Setting up hi practice in an under erviced area a llowed him to take advantage of 
various government incenti ves , as we ll as the new fundin g for mulas for pri vate 
practices that have increased the remunerati on of family doctor to eq ual that of 
pecialists in some cases. Additi onally, there are many opportunities to individuali ze 
one's FM practice to incorporate more speciali zed ta k , which is a great attracti on of 
the fi e ld for Dr. Mai. 
This article has been reviewed by Dr. Joseph Mai. 
A group of six students were three days into the University of Western Ontario 's Rural Discovery Week 
Program in the mid-sized town of St. Thomas, just south of London . This was to be the ftrst taste of community 
medicine that our clas wou ld experience at the end of our fi rst year medical curriculum, and by far the most 
exciting component of the school year. 
I was sitting in the waiting room of a large family med icine clinic that included ix fa mily phy ician , a 
busines office, and fi ve nurses. The clinic was cia ified as a Family Health Group, one of several clinic structures 
created by the government to give fa mily doctors greater fl exibility in deciding their clinic and payment tructure . 
Dr. Joseph Mai is one of the family doctors at this clinic. He j oined the team shortl y after completing hi s 
Fami ly Medicine (FM) residency at the UWO in 2003. Pri or to that, he completed hi s undergraduate training at the 
Univers ity of Calgary, and subsequently pursued his Doctor of Medici ne (MD) degree at the UWO. It was during 
hi s high school years, however, that Dr. Mai' s aptitude in the sciences, combined with hi s admiration for his own 
fami ly physician, helped him decide to pur ue a career in medicine. Furthermore, Dr. Mai' undergraduate research 
in physiology and in oncology, which were further enriched by hi s interacti ons with clinician-scientists, helped to 
expand hi interest in medicine. 
Hi s pur uit of medicine brought him to Ontario and specifica lly the UWO and the London area, where he 
continues to practice. With the current government incentives for fami ly doctors, I wanted to see why students may 
or may not be fl ocki ng to FM a a career, and Dr. Mai' experiences in the MD program can provide insights fo r 
current students. Dr. Mai did not consider FM until much later in his medical education, which is not surprising as it 
can be di ffic ult for stude nts to envi ion what FM encompasses. For in lance, it is often easier to imagi ne the role of 
a head and neck surgeon (the name certainl y provides a clue), a cardiologist, or a neurosurgeon. So why did Dr. Mai 
decide on FM ? I believe his reply below illustrates the importance of keeping an open mind to the various medical 
specialties: 
In my 2"d year of medicine, I became interested in otolaryngology because I thought I 
wanted to be a surgeon and otolaryngology had a good clinical component that I wa 
interested in. It would have allowed me to work with kids a well a adult and I thought it 
was di versified enough to keep my interest. In my 3'd year of c lerk hip, after completi ng 
the surgery rotation, I didn ' t find it as thrilling as I thought I would , so I started looking at 
other option . I still wanted to be a peciali t at the time becau e there was a sense in 
medical schools that fami ly medicine was a default option that wa taken if one couldn ' t 
get into a specialty. 
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I became interested in anesthes ia by the end of 3'd year because I liked the lifestyle and 
was aware of the pending shortage o f anestheti ts, which would produce great 
opportunities in the future. After doing e lectives in anesthesia in 4th year, I found that 
ane thesia wa n ' t what I was interested in because it wa fairl y narrow in it scope. I a lso 
did an electi ve in fa mily medi cine with a great doc tor in Calgary in 4th year. This helped 
me to rea li ze that the interac ti ons that I wanted in medicine were those I would have in 
famil y medicine. 
On re fl ecting, the part I enj oyed most in ENT wa the c linics that I participated in. I didn ' t 
li ke the limited pati ent contact in ane the ia and I didn ' t like the lifestyle of surgery. I 
fo und that famil y medicine had the fl exi bility to allow me to tailor my medical practice the 
way l wanted . 
True to his fee lings that FM would combine the enj oyment of pati ent interaction with the medical 
component o f treating di ease, Dr. Mai's FM residency experience further reinforced his interest. He tra ined under 
Dr. Larry Schmidt at St. Joseph ' Famil y Medical Centre in London. where he gained an even greater appreciation 
fo r the opportunities ava ilab le to fami ly physician . Additionally, Dr. Schmidt, who had a pri vate prac ti ce for many 
years before entering academic medic ine, wa able to hare insight into the bu ine s ide of FM with Dr. M ai. 
Fo ll owing re idency, Dr. Mai worked in various locum , inc luding the clinic in St. Thomas where he was 
quickJ y recruited a a partner. His deci ion to stay in an underserviced area like St. Thomas was upported by the 
government at both the provincial and munic ipa l level : 
The government initiati ve. to he lp attract more phy icians into family practice have been 
very generou . The remunerati on has increa ed ub tanti ally and i equi valent to ome 
pecia lties. The initiatives also give phys ic ian help to run the ir practi ce more effi c iently. 
For instance, the government is pay ing the sa laries for a lli ed health pro fe ional uch as 
nur es and phy io therapi t to work directl y for us. 
I wa able to take advantage of the tuiti on reimbursement a well a the underserviced area 
grant , which helped me to tart my own practice right away with minimal financial 
in vestment of my own. 
Indeed , there are now huge incenti ve for graduating medical tudent and tho e completing FM 
residencies to practice in under erviced area throughout Ontari o 
(www. health .gov.on.ca/english/providers/program/uap/uap_mn .html). Neverthe le . prac ti c ing FM in a mall or 
mid-s ized community can, in some instance , present it own cha llenge and diffi culties regarding call schedules 
and acces to re ource and to spec iali sts: 
Depending on the community that you work in , you will have different levels of pecia lty 
support. I am fortunate in St. Thoma that I have a good core of peciali st that I can 
quickl y refer t . Anything more specia li zed than that can be referred to L ndon, which i 
only a hort di lance away. 1 a ls take care f my own pati ent in the ho pita! and find that 
hav ing ho pi ta! pri vilege i very use ful when a very ill pati ent require more 
comprehensive care. This is be tter for the pati ent a well as giving me the option to treat 
ca. e that cannot be treated within my c linic alone. Being part o f the ho pita! does require 
me to be on ca ll but I haven' t found it to be very onerous. 
From Dr. M ai ' experi ence, it appear that the government ha fina lly started li tening to and addres ing 
the needs of family phys icians by all owing greater fl ex ibility with re pect to the type of practi ce, the amount of 
prac ti ce time, the locati on of practi ce and with whom one decides to prac ti ce with. For Dr. Mai , FM provides him 
with a wide vari ety o f patient to make his practice interesting. Equally important is that FM allows him to be his 
own boss; no dealing and hagg ling with hospita l admini strati on ince knowing all the peciali ts working at the local 
hospita l all ows him to directl y contact them when nece ary. 
" With the new fundin g model , the remuneration i also very good ." Dr. Mai pr jects that with the 
initiatives currently underway, FM will become very attractive and will experience an increa e in interest and in 
recruitment. FM all ows one the fl ex ibility to practi ce medic ine in his or her own tyle and give the individual 
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freedom to change his or her interest to incorporate more specialized ro le and tasks. Finally. it allows one to have 
a life out ide of medicine while also being well-remunerated . 
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Clinical Procedures 
Botulinum toxin injections for cerebral palsy and post-stroke spasticity: an overview 
Brent Mallon. Meds 2010 
This article has been reviewed by Dr. Kellie Leitch. 
Introduction 
Botulinum Toxi n Type-A (BTX-A) has received much attenti on by both medical and non-medical 
ind ividuals. Clinical prepara ti ons of BTX-A such as Botox® (AIIergan Inc, Irvine, CA) are available for cosmetic 
use by famil y phys icians prov iding additi onal education is obtained. When inj ec ted intramuscularly, this tox.in 
prevents the re lease of acetylcholine from presynaptic vesicles in the neuromuscular j uncti on, thus temporaril y and 
reversibly blocking muscle fibres. ' Thi ultimately leads to weakened muscular contractions.2 Although corruno nly 
associated with cosmetics, BTX-A is becoming an accepted pharmacologic treatment for other conditions, as 
injections fo r focal pastic ity econdary to upper motor neuron di sorders such as cerebral palsy or stroke have been 
utilized in medicine for some time and have been covered by OHIP since 2003 .3 Nonetheless, the evidenced based 
support fo r such treatments does not always ex tend as far as randomized controlled trials (RCTs). It is the purpose 
of thi s article to explore the techniques for administering BTX-A to treat spa ti c muscular conditi ons, specifically 
cerebral palsy or po t- troke, while also expl oring the clinical evidence associated with their use. 
Muscular Spasticity 
Spasticity, one component of the upper motor neuron syndrome, ha been previously defined by J .W . 
Lance4 as "a motor disorder characteri zed by a velocity-dependent increase in tonic tretch refl exes with 
exaggerated tendon jerks resulting in hyper-excitability of the stretch refl ex".2 Physical trauma to the central 
nervous system, stroke, multiple sc lerosis, cerebral palsy, and hereditary spa tic parapae is are a ll common causes of 
spasti ci ty. 5 As noted by O 'Brien, spasticity can be viewed as having either ' negati ve ' or 'positi ve' symptoms. 
Negative symptoms, such as loss o f dexterity, decreased coordinati on, or mu cle fa tigue and weaknes can be 
treated conservati vely through physical therapy or living aids.5 O n the other hand, positi ve symptoms uch as 
hyperacti vity, muscle spasm, exaggerated deep tendon refl exes and the persistence of primiti ve re fl exes need to be 
treated with either pharmacotherapy (i.e. oral medication, phenol nerve block, intrathecal or oral bac lofen) or 
surgery (tendon surgery or neuroecto my). 2;5 Thu , it i by addressing the po iti ve ymptoms of spasti c ity that BTX-
A exerts its effect , aimi ng to reduce exaggerated or spastic mu c le ac ti vity to help allow for stre tching and 
antagoni ti c muscle acti vity. 6 Phy ica ll y, the a im of the e injecti on is to re tore balance to affected j oints, while 
preventing contr~tures and bony deformities fro m forming.2 However, physicians should gauge clinical bene fit by 
evaluating functi onal improvement, re li ef o f symptoms (i.e. pain), decrea ing the burden of care or facilitating other 
therapies (i.e. postponing urgical intervention in paedi atri c patients until the skeleton becomes more mature). 
Nonetheless , it is important to emphas ize that pharmacotherapy must be combined with phys iotherapy and other 
forms of conservati ve management (such as orthose or casting) to achieve the bes t improvement o f pati ent 
outcomes.2 
As noted above , c linic ian mu t aim to restore functi onal de fi c it while mitigating negative side effects such 
as excess ive mu cle weakness when admini stering BTX-A for pasti c ity. Thus, the muscular target of the injec tion 
must be considered , the appropriate dose o f toxin must be gauged , and accurate injection of BTX-A must be 
ensured? Phys ical exams should reveal the affec ted muscles , and do ing regimens have been developed to ouide 
toxin use (see O'B rien5 for adult dosing by muscle).2 For children, to ta l dose o f tox.in should be le s than 400 "'units 
or 12 units/kg of body weight for BOTOX®7, although significant he terogeneity ex ists within the literature 
regarding the units/kg/musc le used .8 
In terms of locali zing the appropriate muscle for injecti on, anatomic knowledge and palpati on is an 
accepted technique prov iding the muscle is large and subcutaneous, while the use of electromyographic guidance or 
electrical stimulation i seen as superior for small er muscles like those in the forearm or hand due to improved 
accuracy over anatomic knowledge alone.9;10 However, the above techniques may require special training and can 
be painful to the pati ent, thus they are of limited use in paediatric populations.9 
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BTX-A injecti ons do not appear to be a ociated with any maj or side e ffect , with only focal weakness or nausea 
being reported more o ften in the BTX-A groups when compared to contro l. 11 However, it is known that ome 
patients (< 1%) do not respond to BTX-A while up to 10% o f patients may lose their response to therapy, potentia ll y 
due to the production of neutra li zing anti bodies.);12 T hus, it i · recommended that physicians limi t the do e to no 
more than once every 3 months while using the lowest effec ti ve dose po sible. In the event a pati ent develop 
re i Lance to therapy, a c linic ian lllight consider witching botulinum tox in serotypes (i.e. BTX-A to BTT-B) as they 
are antigenica lly di tinc t. 5;13 
Clinical Evidence 
In adult population. , the maj ority o f re earch has centered around post-stroke or mul tiple scle ro is pati ents. 
In po t troke populati ons, it is believed that BTX-A is effecti ve at managi ng muscular tone . 14 It is less c lear if these 
decreases in tone tran late into mea urable linical benefit for the pati ents. For example, o f the ix 15.20 completed 
RCTs publi hed i n peer reviewed journals and li sted in the Stroke Trials Regi try (www. trokecenter.org) , all fo ur 
tudie 15;17. 19 that gauge the impact of BTX-A injecti ons on mu c le tone/spasti city report stati sticall y significant 
bene fit in the intervention re lati ve to the control group, allhough one tudy17 req uired 1500U dose to achieve 
. .fi d tl 19 d 'd . I . 0 I hr f h fi d ' 15' 17 .19.20 s1gm 1cance an ano 1er 1 not report consistent re u ts over Lime. n y t ee o · t e 1ve stu 1e · · 
exalllining functional improvements report signiticant results, of which two 15;19 did not report consi tent results over 
time (i.e . significance noted at weeks I , 4 and 6 but not 8 and 12). T hus, while it appear studie are able to confi rm 
the neurotoxic effect of BTX-A, the functi onal impac t of thi therapy is still uncertain . 
In paediatric populati ons. BTX-A injection fo r spa ti city i primarily prov ided to pati ents with pasti c 
cerebral palsy, a population where BTX-A's e ffects have been used since the earl y 1990s. 2 1 The u e of BTX-A for 
lower limb spasticity is generally accepted in the literature.9 For example, one recent RCT evaluating 
gastrocnelllious BTX-A injec ti ons fo r pa ti city noted a ta ti stically significant decrease in spasti city a t 8 weeks, an 
increa e in dorsiflexion range and performance goal at 12 weeks, and an max imum voluntary torque and gros 
motor function at 24 weeks. 2 1 However, despite measurable gai ns in performance, patients and their falllilies were 
not significantly happier about their perfo rmance goals when compared to the pl acebo group? 1 The impact of BTX-
A injection on upper-limb spasticity is far le s agreed upon, as a recent ystematic review fo und that there is 
insuffi c ient Level I evidence to support or refute it u e to impact spa ticity/tone, range of mo tion, or short to 
medium functional gains.6 Thu , it appears that the literature hould continue to defi ne the benefits of BTX-A fo r 
upper limb spasticity in CP, while a lso seeking to deterllline what therapie adjuncti ve to BTX-A inj ections will 
benefi t CP outcome 22 
Impressions 
BTX-A as a pharmacotherapy appear capable of reducing spasticity in post-stroke and cerebral pal y 
pati ents. Thi s therapy includes the alleviati on of painful muscle spasms, along with postponing surgery in pediatric 
population by preventing prolonged contrac tures which could deform a joint over time. Much heterogeneity exi ts 
regarding the muscles se lected for injecti ons, the dose of the injections and the means by which muscles are 
identified , which refl ec ts the pati ent centered approach of this therapy. While evidence confmns BTX-A i able to 
reduce muscle tone or spa ti city in these populations, the overall functi onal impact for the pati ent is still unclear. 
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Medicine and the Internet 
Computer-assisted learning in medical education 
Jordan Glicksman. Meds 2010 
Samuel Kraus~, Meds 2009 
Dr. Kevin Fung , Department of Otolaryngology 
Recent advances in technology have resulted in an ever-expanding body of med ical 
literature. Whjle thi growth faces physicians and med ical trainee with a challenge in 
keeping up to date, the technologies that have facilitated the expansion may also 
prov ide doctor and student with new method of learning. Computer-a i ted learn ing 
has the potenti al to enhance medi cal teaching. 
This article has been reviewed by Dr. Jason Franklin. 
Technology and communications have facilitated the tremendous growth of medical literature in recent 
years. 1 Thi has left med ical profess ional with an ever-expanding library of knowledge to be famjliar with . While 
the wealth of new medical information presents challenge for physicians in keeping up with their re pecti ve fi e ld , 
the technologies that have facilitated the recent expansion may also provide an improved means for phys icians to 
learn . Computer-a sisted learning (CAL) may hold an important place in the future of medical educati on in 
undergraduate, pos t-graduate and continuing medical training. 
In Canada, undergraduate medical educati on (UME) takes the form of three or four year curricula. In thi 
time, medical students must acquire the knowledge necessary to pursue post-graduate medical training in both 
general and pecialized residency programs. A a result, medical students are forced to acquire vast knowledge in a 
short timeframe. Time restricti ons in medical training are not limited to education at the undergraduate level; po t-
graduate programs face sirrular time constraints. Residency training programs range from two years in family 
medicine to ix years for cardiac and neurosurgery. At the end of residency, medical trainee are expected to feel 
comfortable as physicians, as they move to practicing medicine independently. 
The Current Use of CAL in Medical Education 
Medical educators already make use of CAL to provide students with increased exposure in their respective 
fi e lds. For example, the Computer-Assisted Learnjng in Pediatrics Program (CLIPP) provides medical tudents with 
a case based approach to learning in pediatrics? Program like this are gaining popularity, as they allow students to 
learn at their own pace. This can allow for students to learn at a time and locati on that is convenient for them, as 
long as there i a computer available to work at. 
In addition to the implementation of CAL in UME, there has been a shift toward the u e of CAL for 
continuing medical education (CME). By 2003 , there were over 11 ,000 online CME cour e available. 3 Practic ing 
physicians are required to obtain 400 CME credits over 5 year . There are six ca tegories of learning that can be u ed 
to obtain CME credits. Up to 25% of this requirement may be met through the "Other Learning Activities" category 
which includes acti vitie such reading imple learning materials like j ournal article or u ing unaccredited online 
courses.3 Additionally, accredited CAL modules may be used to obtain credit when they meet the requirements of 
the "Structured Learning Projects" category , which has no cap for credit hours. 
Advantages of CAL 
CAL application are of particular value for highly visual content, such as demonstrations of surgical 
procedures and technical skill . These kill s typically require patial and visual coordination. While print-based 
learning materials are mainly lirruted to text and image based informati on, CAL can additionall y utili ze multimedia 
capabilitie . CAL can be des igned to incorporate not only text images but also video to enhance tudent learning. 4 
Interactive features of CAL, such as quizzes and learning games, can augment the learning process by providing 
feedback in a manner that makes student feel comfortable?·' 
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Costs of Implementation 
While the convenience of CAL i attractive, as with any new technology, co t i often a concern . 
Nevertheless, widespread use of CAL modules can be very cost-effective. For example, in 2005 , the average 
development co ·t per CLIPP case ess ion was approximately $6, and this amount will decrease as more student 
continue to u e each ca e.2 Jn additi on, replacement o f teaching with CAL has the potential to free up the time of 
medical chool lecturer to teach in o ther capacitie , uch as small group ses ion . Furthermore, CAL ha the 
potential to enhance teaching at di stant locati on uch as satellite campuses, rural setting and in developing nations. 
CAL and Other Learning Methods 
Adults have been hown to learn optimally whe n the ir learning i self-directed .6 Thi has resulted in a trend 
away from traditional lec ture and seminar-ba ed teaching and towards the implementati on of more self-directed 
learning in medical curri cula. In se lf-direc ted learning, the learner identifies the knowledge in which they are 
de fi cient and then allempt to learn based on the ir indi vidual needs. Computers may be able to assist in this proce s 
by providing interac ti ve tools such a quizzes and learning games to a id the student in determining what information 
to pursue. 
Currentl y, there i debate as to the effec ti vene o f CAL a a teaching modality. There are everal studie that 
have compared the use o f CAL to other methods o f educati on. Many o f these studie show that there i no 
ignificant difference in knowledge and skill re tenti on between tho e taught didac ti ca lly or by eminar when 
compared to those taught by computer teaching module , but there are some tudie ugge ling that o ther form of 
teaching (e.g. didacti c lecture) are till superior. 2· 4· 7·9 
The Future of CAL 
While re earch till ongoing into the e ffecti vene of CAL for medical education, thi new learning 
modality is a rising form of medical teaching. The As ociati on of American Medical Colleges (AAMC) ha 
established MedEd Portal, a peer-reviewed collection of online teaching tool . Thi re ource contain a databa e of 
learning re ource that inc lude tutorials, virtual pati ent and ca e-ba ed learning among other medical education 
resources. 
10 
Not onl y doe the MedEd Portal provide ea y acce s to CAL modules, but it al o provides incentive to 
academic phys ic ians to create more CAL tool by providing the ir work with recognition a a peer-reviewed 
publication. Initi ati ve uch as this will like ly increa e the produc tion of CAL module . 
The use o f computer-ba ed teaching in medicine has the potenti al to change the way medicine i taught to 
both current and future generations. Be tween the conve nience afforded by L , enhancement over current 
learning modaliti e and increased recogniti on for publi hing AL module , there appear to be a bright future for 
computer-ass i ted learning. 
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Histor of Medicine 
In the beginning there were apothecaries 
A historical perspective on the emergence of general practice, the emergence of fami ly medicine, and the research 
agenda of family medicine. 
Adam Garber, Meds 2010 
Ra-;.a Naqvi, Meds 2009 
The emergence of general practice a an academic discipline can be traced over a lmo t 
two centuries. Major events inc lude the establi hment of the Co llege of General 
Practice, the identificati on of a defined body of knowledge, the estab li shment of criteri a 
for certificati on, and the change of the co llege ' s name to the College of Famil y 
Phy icians. Of particular importance a we ll is the development of re earch network 
and methods that amplify on the unique aspec ts of family med ici ne. 
This article has been reviewed by Dr. Jeffrey Freeman. 
The hi tory of family medicine in North America is a rather new one. Within its history there are periods of 
parti cular strength followed by period fraught with struggle. Despite these natural ebbs and fl ows, farru ly medicine 
ha advanced medical understanding and practice both in the cience and the art. That i , family medicine ha 
advanced the medical understanding of care for the individual while at the arne time contributing at a scientific and 
epidemiological level to the body of medical literature. This es ay will outline a brief history of the development of 
general practice and then family medicine as it emerged from general practice. The essay will also addre the 
hi tory of the re earch agenda of family practice. 
The history of general practice begins si milarly in Canada and the United State in the earl y I 9th century as 
both countries clo ely followed the Briti h model. There were physicians, surgeons, and apothecarie 1•2• Phys ic ians 
were trained through university course work or apprenticeship and were the progenitors of what we now know as 
pecialist 1• For the most part, they provided care for the affluent. The surgeon were trained in barber schools and 
were not permitted to pre cribe medications. The apothecaries began as shopkeepers that provided medicines. 
Interesti ngly, the apothecaries took on the role of conducting initial clinical investigation . The Apothecarie Act of 
18 15 advanced both the privileges and the responsibilitie of apothecaries. The Act required candidates to complete 
a pharmaceutical chemistry exam and an exam on the theory of the practice of medici ne. A well , candidates were 
required to complete a five year apprentice hip 1• These requirement allowed the apothecaries to produce income 
through the prescription of their medici nes as well as through their medical practice. It i from the e humble 
beginnings that the 'general practitioner ' was born . It is also intere ting to note that David Woods, a renowned 
medical writer and educator, uggests that the general practitioner in North America predate the existence of the 
general practitioner in Europe due to the dispersed ettlements and mobile colonies which necessitated the ability of 
one person to perform surgery, practice medicine, and prescribe medication 1• The general practitioner enjoyed a 
number of years of stability despite some public concerns that due to the lack of a more rigorous applicati on system, 
some general practitioners were under-educated. 
By the end of the 19th century however, as the specialist movement gained momentum, some doubts existed 
as to the future of general practice. Even Sir William Osler expressed thi doubt with respect to general practice in 
an urban setting 1• The Flexner Report of 1910 furthered the dominati on of speciali st medi cine. The Flexner Report, 
entitled 'Medical Education in the United States and Canada' , led to the standardization of the medical curriculum 
and created a link between medical schools and established uni versities. As a result mo t clinical teaching was now 
taki ng place in urban teaching hospital 1'2• Gutierrez and Scheid point out that by 1935 hospitals became the centre 
for teaching and technology, specializing was valued highly and required a residency period, as the practice of 
medicine became a profession for the wealthl. The hospitals, now as speciali st centres, left an uncertai n role for the 
UWOMJ 77(1 ) 2008 
- 17 -
general practitioners who continued to practi ce within these very centres to a certain ex tent. The obse ion with 
scientific and technological advancement that re ulted from the World War II placed even more glory on the 
d I. dl ,2 shoulders of pecialists and the number of student entering the fi e ld of genera l practice consequently ec me · 
The College of General Practi ce of Canada, founded in 1954, published a bill of rights for general 
practitioners3. The College was born out of a need to both redefine the role and revita li ze the image of the general 
practitioner. Its initi al mi ion was to improve educational tandards and opportuniti es, certification tandards, 
standards of practi ce and to he lp define the general practitioner's ro le in the hospita l and in the office . 
Understandably, before implementati on of any change, the college struggled with the prec i e definition o f their 
ambitious objecti ves. Two centra l diffi culli e proved to be interre lated and took more than a decade to resolve; first, 
the identification of the body of knowledge that is to be ubsumed under the domain of genera l prac tice and, second, 
the is ue surrounding the college's responsibility to certify its members. It wa in 1967 that a document entitled 
Graduate Training in Family Practice both specified training requirements but also outlined the body of knowledge 
that concerns family phys ic ians4 . The comrnillee re ponsible for thi document also enlisted support from Canadian 
medical school that year. It i noteworthy that famil y medic ine re idence programs at both McMaster University 
and the Uni ve rsity of Weste rn Ontario precede thi document by one year. It was a lso in 1967 that the college was 
renamed a the College of Family Phy ic ian 4, a name which the college pres ident , lrwin Bean, opposed but later 
acknowledged its necessi ty. Not surprising ly, thi flurry of progress and newfound purpose that seemed to be 
weaved into the new name of the co llege, corre lated with the incepti on of Canadian medicare in the 1960s. 
Concurrently, in the United States, the Millis Report, the Folsom Report, and the Willard Report were 
published independently by the American Med ical Association in response to the increa ing public di sapproval of 
the fragmented delivery o f care, the inacce ibility to service, and the "deper ona li zati on" of care2. Thee report 
uggested the need for each ci ti zen to posses a personal physic ian who i en iti ve to life context, the impact of 
illness and the importance of therapeutic option . It is the opini on of some that family medici ne wa a natural 
reacti on to the counterculture o f the 1960s2. Stephens argue along the e line when he peak of agrarianism, 
humani m, utopi ani m, consumeri m, and feminism in relation to the birth o f family medici ne in North Ameri a5. 
The di cuss ion surrounding re earch in family medicine began o n after the emergence of family 
medic ine a a di c ipline in Canada and the United State 6 . As Herbert explain , the re earch agenda of fami ly 
medicine wa ca lled into que Li on as early a 1966. The initial idea wa that research in family medic ine would 
focu on di agno tic te ting, interpretation of ymptoms, larger epide rni ological tudie , a well as development and 
behaviour. However, thi no tion was ex panded during the 1970 to include ther areas o f tudy uch a health care 
ervice , clinical trategies, biomedical sc ience , and the o ia l c iences6. The tudy Group on Famil y Medicine 
Re earch which took place in 1982 articulated the areas of re earch to which family medic ine could make unique 
contributi ons and hi ghlighted the importance of re earch e lec tive time for students7. Perhap one of the mo t 
important shifts in the research agenda o f fami ly medic ine involved recogniti on of the importance of each 
indi vidual' s socio-cultura l and environmenta l c ntex t in under tanding health and behavi or. Thi idea was 
highli ghted by Nigel Stoll in 1987 and by Culpepper in 199 1 and req uired a shift in research methods to account for 
patient contex t in the de li very of medical e rvice and the experi ence of illness6 . 
Since the incepti on of famil y practi ce, it wa c lear that the family phys ician's office po sessed a remarkable 
amount of data re lating to disea e proces e. and outcome 8. It i this sort o f data, Ryan argued , that could he lp 
address centra l issues like diabete , back pain , and the common cold and he lp to "bridge the performance gap" and 
"answer rea l-world re earch que ti on ". While the potential ha always been recognized and ll1e particular area of 
benefit have long been deba ted and re fined, it is the " harves ting" of the data that has pre ented o ne of the o- reatest 
0 
ob tac les to research in famil y medic ine. Until the earl y 1980s, research in fami ly medicine was praetice-ba ed and 
therefore, depending on the demographics of the surrounding community , only certain research questions could be 
adequate ly addressed. During the 1980s, a m ve wa made towards practice networks and in 1995 the Federation of 
Practice-Ba ed Research Networks (FBPRN) was born in the United States with the hope o f poo lin o data 
brainpower, and resource 8. Since then practi ce-ba ed re earch ne tworks are succeeding in the production of o und 
re ~arch databa es. ~erhaps the _most use~ul aspect of practi ce_-ba~ed research networks i the ir abi lity to trac k many 
pallent for long pen ods whrch 1 conducrve to th rough longrtudrnal studres. Indeed research in family practice ha 
evolved to inc lude large scale longitudinal studies conducted through collaborative re earch network 9_ 
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From apothecary to genera l pracuuoner to family doctor, the hi story move toward increasing 
organization and increasing academic ambition . De pite the many important definiti on and redefinition , and the 
advancements of mi ssion and respon ibility , a similar vein string the hi . tory together. That is, each tep in thi 
progre ion, inc luding the research endeavours, eem to be guided by the de ire to care for the person whil e 
cognizant of intricate ocial contex ts. 
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Trans Fats: Health Risks and Policy Considerations 
Jonathan Klein, Meds 2010 
Jennifer Clara Tang, Meds 2009 
Public attention has recentl y focused on the use of trans fats in commercial food 
preparati on and efforts to ban them from commercial products. Trans fa ts have been 
shown to increa e the ri k of coronary heart di ease more than any other calorie source, 
inc luding other types of fa t. Denmark and The Netherlands have already implemented 
substantial reducti on in trans fa t content, though each country achieved thi s goal 
through sub tanti all y di fferent means. We review the chemistry and health ri sks of trans 
fa ts and di cuss pas ible policy opti ons to reduce trans fat consumption in North 
America. 
This article has been reviewed by Dr. Chris Grant. 
Introduction 
Many recent media reports have foc used on efforts to curb the levels of trans fa ts in food. The issue has 
become a hot topic in public di scourse with the recent ban on tran fa ts enac ted by New York City. These reports 
often contain little sub tanti ve information instruc ting reader about what trans fats are . what evidence exists that 
they pose a health hazard , and what polic ies have been implemented to attempt to curb their u e. In thi s arti cle, we 
seek to provide information on these topics and explore existing options for North American society when 
considering the issue of banning trans fats. 
Chemistry and Use in Food 
"Fats" is a term u ed by chemists to describe a chemical structure in which 3 "fatty acids" (long chain 
carbon molecules with a -COO at one end) are attached to a ha rt chai n of 3 carbon atoms called "glycerol" . From 
a nutriti onal viewpoint, " fats" are o ften subdi vided into two categories: aturated and unsaturated . Unsaturated fat 
are made of fa tty ac id chains which conta in at least one double bond, while saturated fa ts have none. These fats are 
typically liquid at room temperature, since naturally occurring unsaturated fa ts typically have their double bo nd in 
the c is ori entati on. Thi s des ignati on indicates that the carbon atoms on either end of the double bond are on the arne 
side o f the molecule creating a bent structure preventing the molecule from packing closely to one another and 
raising the compound 's melting point. Trans fats are unsaturated fa t with carbon-containing group oriented on 
opposite sides of the double bond (Figure 1). Thi configurati on creates a u·aight chain o f carbon atoms allowing 
for molecules to pack closely together and cau ing a solid state at room temperature. 
An unsaturated fa t i termed "po lyun aturated" if it conta ins two or more multip le bonds in any one fatty 
ac id ; unsaturated fats with onl y one multiple bond are "monounsaturated ." Polyunsaturated fats are commonly 
known simply as "unsaturated" fa ts. Tran fat are a lso ca lled trans fa tty ac id (TFAs), since the trans-oriented 
double bond is located on the fatty acid part of the fa t mo lecule. 
- 20 - UWOMJ 77(1) 2008 
FIGURE 1: A) Diagram of a trans fat , tran -9-octadecenoic acid . Note that the carbon containing group appear on 
oppo ite ides of the double bond . B) Diagram of ci -9-octadecenoic acid, also ca lled oleic acid. The carbon 
contairung groups are on the same ide of the double bond . Thi s is the c i configurati on of the fatty ac id shown in 
partA. 1 
Tran fat are prod uced indu tria ll y from the partial hydrogenati on of vegetab le oi ls using metal ca taly ts, 
e liminating ome of the double bonds. The advantage of this proce s, from the food industry's per pec ti vc , i that 
e liminati on of ome double bond makes for vegetab le o il that are more solid (" preadable") rather than liquid , and 
which take much longer to go rancid (ie . to have their double bond o!Ud ized during torage). Being ab le to pread 
one' ' butter' with a knife i important to many con umer ; and he lf life i very important in the food indu try. 
Unfortunately, removal of ome double bond takes one back toward saturated fat with their undesirab le 
health con equences; and perhaps worse, the ame processe that remove ome doubl e bonds also create some trans 
double bond in other pl aces in the fats . The e fat are o ften found in pread such as margarine, pas try dough and 
other commercia lly prepared foods. TFAs are found natura lly in small amounts in the meat of animal which chew 
their cud , such a cattle and sheep, but they only account for around 0.5% of total energy intake from these meats2' . 
Evidence Linking Trans Fats to Heart Disease 
Fat are an essential part o f a balanced die t. Canada 's Food Guide recorru11ends between 30 and 45 mL of 
fats per day, though it tresses that the e hould come from (po ly)un aturated fats, while limiting saturated and tran 
fat intake4 . tudie have demonstrated that eating mo tl y polyunsaturated fat and limiting consumption of saturated 
and trans fat prov ides significant protec tion against heart di sea e5. 
Hi gh die tary con umption o f tran fat has been linked to increa ed ri k o f myocardi al infarction and other 
coronary events. Using data on over 85 ,000 female nurses from the Nurses Health Study, Willett e t a l demon trated 
that the re lati ve ri sk of coronary heart di sease (CHD) between the populati on quintiles with the highest and lowest 
trans fat consumption was 1.50 (1. 12-2.00 95% confide nce interval)6. Ascherio e t a l demonstrated a relati ve ri sk of 
2.44 ( 1.42-4. 19) in a smaller, non-gender-restricted tudy conducted in Bo ton 7. These re ults demon trate 
ubstantial increa es in CHD related to high trans fat intake. Other studie have examined the impact of tran fat s on 
known ri sk factors for CHD. TFAs in the diet have been shown to both lower erum HDL and raise LDL 
cholesterol, both independent ri sk factors for CHD. These effec ts on serum lipids are seen in both men and women8. 
Despite these data, fat remain a maj or source of calories for many people. People often find it difficult to 
completely e liminate a source of calories from their diet; they are more likely to replace a ource of calories with 
other food that prov ide similar caloric intake . So, it i instruc ti ve to compare the health ri sk posed by tran fats to 
those of similar compounds with which they might be repl aced. 
Repl acing TFA with any other calorie source has been shown to reduce levels of LDL, or "bad 
cholesterol"2•3. Reduced LDL levels decrea e ri k for CHD. Studies have al o demonstrated that replac ing TFA 
with other fats increase serum HDL levels. Low HDL levels have also been linked with cerebrovascular and arterial 
di ease, o eliminati on of TFA from the die t may also reduce the ri sk of the e di eases. In a diet in which TFAs 
provide 2% of calories, replacing the calories from TFAs with an equal mix of carbohydrates, aturated, mono- and 
polyun aturated fat , reduces the incidence of CHD by 3.8%. If the TFAs are replaced by an equal mixture of mono 
and polyunsaturated fats, the reduction is 5.4%9. 
Epidemiologic tudie , however, have sugge ted a stronger reducti on in heart disease if TFA are 
e liminated from the diet. Repl acement o f TFAs by equal parts carbohydrates, aturated, non-TFA mono- and 
po lyunsaturated fats has been estimated epidemio logically to confer a ri sk reducti on of over 25%. It is like ly that the 
true ri k reducti on fall s somewhere in between these estimate , which would indicate a significant ri sk reducti on 
from elimination of dietary TFAs9. 
Some recent calculation suggest that significant reductions in TFA levels in the United State could 
prevent between 72,000 and 228 ,000 cases of heart di ease a year, or up to 19% of the total annual incidence2. 
Reduction or e liminati on of TFAs would go a long way to reduci ng a very significant cause of morbidity and 
mortality. 
Policy Implementation 
Efforts to ban indu trially produced TFAs in food have been widely covered in the media. Recent pre s 
coverage in North America ha focused on the ac ti on of New York City ' municipal government, which instituted a 
ban on TFA in 2006. But New York 's effort is only one in a long string of initiati ves aimed at curbing people' 
intake of trans fats. Similar actions have been undertaken around the world , and have used different techniques to 
achieve different result . 
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The m t common path to reducing TFA consumption ha been through government regulation of the/ood 
industry. In re pon e to Wille tt et al. 's 1993 Lancet paper demonstrating the adverse health e ffects of TFAs , the 
Dani h Nutriti on Council embarked on an ex ten ive rrussion investigate these effects further 10. In a series of reports 
the subject, they demon trated the wide body o f data that had arisen demonstrating the adverse health e ffects ?f 
TFAs, such as increased CHD incidence, and the absence of health bene fits. They concluded that TFA u ed 1.11 
indu tri a l and bakj ng proce ses are respon ible for the majority o f Dani h TFA consumption, and advocated for thelf 
e lirrunation from the food upply11.1 2 The Council led a long camprugn again t industrial TFAs, in response to 
which the government of Denmark enac ted the world 's ftrst nati on-wide TFA regulati on in 2003 10. The Canadian 
House o f Conunons considered a similar measure in 2004, but the bill fai led when parliament was dissolved prior to 
the genera l e lec tion of that year. Despite the failure of that bill , the issue continued to make waves at all level of 
government in Canada. A 2006 report by the federal Tran Fat Ta k Force recommended lirruting trans fat content to 
two percent of total fat in preadable margarine and fi ve percent of tota l fat in a ll o ther foods 13. At the municipa l 
level, Toronto 's med ical offi cer o f health , Dr. David M cKeown, is cheduled to issue a report by September 2007 on 
possible strategie. for eliminating trans fats in the c ity 14 . 
. f . k 15 Monitors in Denmark have verified that the legislati ve efforts have succeeded in reducmg trans at mta e 
As the effort is ti II frurly recent, no long term tudies have yet tudied whether the effort have yie lded sub tantial 
public health benefit. Continued monitoring and follow up of TFA reduction effort mu t been undertaken to 
determine whether the effort has prevented C HD in the Dani sh population . 
In a parallel ucce to that seen in Denmark, the food industry in The Netherl and achieved a ignificant 
reducti on in tran fats in their nation's food uppl y, without need for government intervention. A maj or tipping point 
came from a 1990 publication by Korver and Katan aided by the Anglo-Dutch food corporation Unilever. The tudy 
demonstrated that TFA lowered HDL and ra i ed LDL level in the blood . After media reports di seminated thi 
knowledge, Unilever decided in J 994 to remove TFAs from it commercia l pread , such a margarine. Sen ing a 
hi ft in the market toward healthier products and seeing one of the industry leaders takj ng uch a step, other 
companie. fo ll owed Unilever 's lead 16. Within two year of Unilever ' deci ion, most retrul margarine old in The 
Netherlands contained onl y trace amount o f TFA. In 2004, another indu try- led initiati ve ucce fully reduced the 
amount of TFA in fryi ng oil used by cha in re taurant . One estimate place the number of myocardial infarctions 
avoided by the Dutch initi ati ve at 1,750 cases per year9. 
Lawsuits against corporation have al o been u ed to reduce companie ' use of tran fat . The effort o f a 
group in California called BanTransFats.com, Inc. led Kraft to e liminate trans fat from Oreo cookjes and to reduce 
or e lirrunated TFAs from over 600 other product . The group al o applied pre sure on McDonald ' in 2003 , forcing 
the company to publicize that it had not changed it cookjng o il to one lower in trans fat and continues to work to 
achieve further red uction in conunercial TFA use 17. 
Discussion 
The Dani sh and Dutch experiences demonstrate public receptivene to reduction of TFAs in food. They 
a lso illustrate contrasting strategies for achieving this goa l. One rrught , then, consider which approach i more 
suitable for Nortb America. Kalan suggest that the Dutch appr ach may not be a exportab le to o ther countrie a it 
may initi all y eem. The Dutch adhere to a traditional method for crafti ng ocial olution without government 
interference, derived from thei r co ll aborati ve approach to water management. This etho ha tran lated to other areas 
of Dutch society; labour connic ts and other i . ues are typica ll y ettl ed through negotiati on, rather than legi lation or 
arbitrati on9. 
Though lackj ng the Dutch co ll aborative traditi on, North America has long u ed marke t forces to advance 
societal change. A market-based soluti on may well be the be t path toward TFA reduc tion in Canada and the United 
State . A major driving force in the Dutch experience wa the deci ion by indu try leader Unilever to reduce TFA 
in thei r prod ucts. Competitors en ed thi hi ft in the market and followed uit, le t Unilever further inc rea e the ir 
market share at the expense f the competiti on. 1f a maj or North American corporation were t e liminate TFA it 
could start a simi lar cascade through the food indu try and cause the same result as in The Netherlands with~ut 
government intervention. 
North American corporati on have thus far been unwilling to change their pra ti ce . A maj or problem 
commonl y c ited by North American manufacture r. is that oybean oil , the major edible oil u ed in North America 
contains alpha- linoleic ac id, which is unstable and thus must be parti a lly hydrogenated to make it suitable fo; 
cookj ng. Kalan points to McDonald 's as emblematic o f this res i tance; the company has yet to reduce TFA leve l in 
the cookj ng oil u ed in their North American franchi ses, despite the chain' uccessfu lly reducing TFA levels in 
their Dutch restaurants8. Though acti on from public- interest group did cause McD nald 's to admit to this re i Lance 
and public ize the TFA content fit cookjng o il , the activity ha not yet cau ed McDonald ' to adopt ingredie nt 
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lower in trans fats 17. Perhaps the publi pre sure to reduce TFA content in North America has not ye t reached the 
levels een in The Netherlands in the 1990's. However, given the recent med ia coverage given to TFAs, increased 
scientific knowledge of the ri sk of T FAs, the Trans Fat Ta k Force ' s recommendati o ns and Or. McKeown' 
forthcoming report, Canadian public support for TFA reducti on could be expected to ba ll oon in the near future. A 
maj or public outcry could create the market forces necessary for an indu try-wide shi ft imjlar to the one seen in 
The Netherl ands. 
On the other hand , Denmark ha achieved similar success to T he Netherl ands by legislating TFA level 
downward . Both the TFA-limiting bill introduced into in the Hou e of Common and the government of New York 
C ity' recent decree de mon trate that North American policy-makers favour legislating TFA levels, rather than 
waiting for indu try to make a change in their practice that might never happen. 
The American Food and Drug Admini tration has already required that tran fa t content be included on 
food label , and it Nutrition Sub omm.ittee of the F od Ad vi ory Comm.itt e concluded that trans fa t are " more 
adverse" than sa turated fats in te rms of increa ed ri sk o f coronary heart disease 18• A mentioned prev iously, the 
newe t edition of Canada' Food Guide, published in 2007 , specifically cautions that tran fats hould be avo ided as 
much as po sible. The e may be een a first s teps towards further regulation o f T FA levels in food , though firm 
legi lation on a nati onal level has not been considered since the failed 2004 Commons bill. 
Gi ven the lack o f industry-dri ven change seen in North America to date, governments could be persuaded 
to introduce hard hitting legislati on if prompted to by the public. Some success has a lready been . hown by 
BanTransFat. com, Inc., though wide pread reduction of TFAs have not yet been achieved through liti gation 17. 
Increased public awareness o f TFAs coupled with failure of market forces or legislati on might lead to uccessful 
lawsuit achieving dramatic reduc tions in TFA content in the future. 
Conclusion 
The health ri k po ed by con umption o f trans fa ts are we ll doc umented . Increa ed level of erum LDL 
and lowered HDL increase one's usceptibility to coronary heart disea e and other problems. Replac ing trans fat 
content in food with a combinati on o f other types o f fat provides substanti al reduction in ri k o f coronary heart 
disease, and some studie suggest that up to 19% of coronary heart di sease case could be prevented through TFA 
reducti on initiati ve . 
As Canadi ans become more aware of the ri sk posed by TFA consumption and the alternati ves to eating it, 
they may demand a reductio n in TFA levels in their food. Whether market forces, government legi lati on or legal 
action dri ve thi change remains to be seen, but reduction ofTFA to levels similar to those seen in Denmark and The 
Netherland will likely be a reality in the near future. 
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Thinking on our Feet 
A Clinical Perspective on Colorectal Cancer 
Amber Mene;.es, Meds 2009 
Case 
Mr. P . Smi th is a 60 year-o ld gentleman who presented to hi fami ly phys ician 
complaining of a ix week hi tory o f abdominal cramping and tools streaked with 
blood. He a t o menti oned that hi bowel hab its had changed, with increasing 
constipation. 
Upon obtaining a patient hi tory, Mr. Smith 's phy ic ian noted a die t high in 
red meat and 40 years of tobacco u e. No fam.i ly history of large-bowel di ease was 
present. A digital rec tal exam was normal, but the fecal occult blood te t tested gui ac 
positive. After referral to gastroenterology, a colonoscopy was perfom1ed, and a lesion 
was identified in the di stal colon. Pathology revealed an[JMH2] adenocarcinoma of the 
colon. 
This article has been reviewed by Dr. John Howard. 
Introduction 
Colorectal cancer is the commonest cancer in males and females combined. In the developed world , this 
di ease i second only to lung cancer for new cases that occur each year. 1[JMH3] Annually , there are approximate ly 
130 000 case and 57 000 death in the US due to colorectal cancer.' The incidence of colorec tal cancer ranges 
between the ages of 40 to 75 1, although it most commonly arises in individuals over the age of 50.2 
Regardles of etio logy, the majority of colorectal cancers are due to tran formation of tubular or vi llous 
adenomatous polyps (protrusion of ti ssue above the mucosa).1.2.3 Adenomatou polyps have the potential to be 
malignant, e pecially if they are >2cm, ess ile (fl at-ba ed) , and vi llous (papi llary) in nature.2·3 However, <1 % of 
polyps ever develop into cancer. 2 
There are several ri sk factors that predispose to colorectal cancer. The e include age (after age 50), diet, 
tobacco use, a history of ulcerati ve coliti and hereditary causes. 2.4 Die ts high in animal fa t and calorie , such as 
found when ingesting red meat and processed meat are implicated in increasing the risk of th.i s di sease.2 Although 
the exact mechan.i m is unknown, 1 one possible hypothesis is that eating an.imal fat leads to greater number of 
anaerobe in the gut, and their ubsequent action on bile acids forms carcinogens.2 Another lifestyle fac tor linked to 
development of colorectal cancer is cigarette smok.ing, particularl y after a smok.ing hi tory of 35 year or more.2 
There i a defin.ite geneti c component. With no close relative affected , the ri sk of colorectal cancer is 1 in 
50.3 If an indi vidual has a first degree relative (parents, siblings, children) who has had colorectal cancer, that ri sk 
increases to 1 in 17, and then to 1 in 10 with two fir t degree relatives affected .3 Hereditary syndrome such a 
fami lial adenomatou polyposi s (FAP) and hereditary non-polyposis colorectal cancer (HNPCC) also play a role in 
increasing the ri sk of cancer. FAP is an autosomal dominant disorder that can produce thousands of polyp in 
affected individuals, uch that the ri sk of colorectal cancer is close to 100% by age 40.5 HNPCC in volve mutations 
in genes encodi ng enzymes in volved in DNA surveillance; defective enzymes lead to lack of repair and cancerous 
mutations.5 The important point in HNPCC i that cancers tend to ari e de novo rather than in polyp . 
Screening 
A variety of screen.ing tests are available, yet screen.ing rates are low. A possible reason is that profess ional 
organ.i zati ons have not yet come to a consensus as to wh.ich te t is the be t or most prefened .6 However, they all 
stre s the importance of screening of eligible adults (ie. over age 50).6 According to the American Cancer Society 's 
C l.inical Guidelines for Colorectal Cancer Screening, the strategies reconm1e nded are any one of the fo llowing: 1) 
annual fecal occult blood testing (FOBT); 2) flexible sigmoidoscopy every 5 year ; 3) annual FOBT and a fl exible 
sigmoidoscopy every 5 years; 4) colonoscopy every 10 years. 7 
Fecal occult blood tests 
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There are evera l type of FOBT , but the mo t commonly u ed is the Haemoccult test, where guiac filter 
paper undergoe phenolic ox idati on in the pre ence of hemoglobin in stool. 5 Ideall y, a FOBT should con i t o f thre~ 
erially obtained sample o f tool, completed by the pati ent at home and then mai led to the physician or lab ratory . 
Utilization of thi creening te t has been reported to cause a 14-16% reduction in the re lative ri k o f colorecta l 
cancer mortality when performed bienni ally over 10 years .9•1° Furthermore, FOBT can de tect 10 m.L o f blood 
lo s/day in 67 % of patient . and 20 mL or more o f blood loss/day in 80-90% of patient .5 The advantage o f FOBT 
are that it i inexpensive and cause the patient onl y little di scomfort. 5 However, a key limitation of the Haemoccull 
test i that 509'< of patient wi th colorectal cancer te t negative, due to the intermittent bleeding patte rn o f the 
di ea e. 2 In add ition. the fal e po iti ve rate increa e by 2- 10% in older per ons when samples are rehydrated (which 
lightl y increa e en itivity). 
Flexible sigmoidoscopy 
Followi ng a po itive FOBT result, a workup of the colon is rec mmended . Flexible sigmoido copy i 
u ua ll y the next step a. it i quick, safe, simple, and ha high ensiti vity and pecific ity.5 This te t is performed 
wi thout sedation in a patient that has received a laxati ve or an enema, and examine the di ta l 65 em of the colon.5· 
Unfortunately, thi doe leave the proximal ha lf o f the large bowel unexamined , yet thi limitati on may not be 
cri ti cal. Evidence show that adenomas of the di ta l o lon are more like ly to progre to malignancy than those 
located in the proximal colon.5 
Colonoscopy 
A trai ned endo copi t exami nes the entire co lon via thi s procedure, which require patient to undergo light 
edati on and follow a liquid diet with u e of laxati ve beforehand . During the procedure polyp and early cancer 
can be removed .8 Colono c py i the colorecta l cancer reening te t with the highe t en itivity and pecificity, but 
that doe not make it the best te t. 6 It is ex tremely ex pen ive (the median charge for co l no copy in Canada i $606 
US dollar )6, pose a greater ri sk of perforati on (2 per 1000 proced ure [JMH4] , ver u 1 per 10,000 for 
igmoido copic procedures) and more ri sk o f compli cati on due to edative u e. 3·8 But for tho e patients without ri k 
factor trying to choose between creening opti n , colonoscopy might eem attracti ve a it only needs to be 
perf rmed once or twice in a life time. thus maximizing compliance.6 
As there i no ideal cour e of action in term of creening, phy ician hould di cu the pro and con of 
each test in li ght of patient pre ference. Importantl y, the phy ic ian need to keep in mind that after the age of 50, it i 
recommended that all patient. undergo some form f creening for o lorectal cancer[JMHS] . 
Clinical Presentation 
Signs and symptoms vary depending on the ite of the cancer. Cancer of the right colon (cecum, a cending 
colon, proximal tran verse colon) pre enl with fatigue, weight lo s, and hypochromic microcyti c anemia. 2.3 
Obstructi on or change in bowel habits is rare a the s to I are mo tl y liquid in the area o f the right colon.2 Stool 
appear normal but occult blo d loss can occur duet ulcerati on of le i n in the ri ght c lon.2 In contra t, the le ft 
colon ha a maller lumen and t o l ha a emi s lid c n i Leney in thi area. 1 uch, ancer of the di tal tran ver e 
and de cending colon tend to ob truct pa age of l o l, cau ing abdominal pai n and a ltered bowel habit 
(c n tipation, diarrhea) .I.2.J Perforati on occasiona ll y develops, with focal evere pain and tenderne .1•2 too l appear 
treaked with blood. 1 La Ll y, cancer of the rec tum presents most commonly a bleeding with defecation. 1 Narrowed 
stools, pain , and tene mu (feeling o f incomplete evacuation ) may al o be pre ent. 1•2 
Diagnosis and Management 
Colono copy is per~ rmed on tho e individuals with po itive FOBT or with le ion een n 
igmoidoscopy; all lcsi n · arc then rem vcd for patho logic examinati on. 1 If cancer i diagnosed on the ba i of 
hi to l gy, further workup inc lude. a thorough phy ical examinati on, abdominal T , che t X-ray, bioche rnica l 
asse. sment of liver functi n, and routine laboratory le ts to evaluate metastatic di ea e, anemia, and vera ll 
conditi on. l.2 Tumour recurrence can be predicted by e levation of erum carc inoembryonic antigen (CEA) level .2 
H wever, thi s test i not spcci fi e, and e levated level are found in 709'< of pati ent with col recta l cancer. 1 
Progn si for pati ent with ~o l orecta l cancer is linked to the degree o f tum ur penetrati on into the bowe l wall (T ), 
the presence of lymph node tn v lvemenl (N), and the pre ence or absence of di tant meta ta e (M ) 1 (Table 1 ). 
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Table 1. Staging of and Prognosis for Colorectal Cancer 2 
Sta_ge Pathologic Description Approximate 5-Year Survival , % 
Dukes TNM Numerical 
A TlNOMO I Cancer limited to mucosa and submucosa >90 
B1 T2NOMO I Cancer ex tend into musculari 85 
Bz T3NOMO II Cancer ex tends into or through sero a 70-80 
c TxNlMO III Cancer in volves regional lymph nodes 35-65 
0 TxNxM1 IV Distant metastases (i .e. , li ver, lung) 5 
Ideally, curati ve urgery is attempted in 70% of patients without metastatic di ease.1'3 Depending on the 
cancer ite, surgery can consist o f hemicolectomy (right or left colon), sigmoid colectomy ( igmoid colon), anterior 
re ec tion (low igmoid or high rectal tumours) , and abdomi no-perineal (A-P) resecti on for low tumours in the 
rectum.3 After total resection, patiems hould be followed for 5 years with emiannual physical exami nati ons, yearly 
blood chemi try mea urements, and trienni al endoscopic survei llance of the large bowel? In patients with metastatic 
di ease, subsequent resection is sometimes attempted in otherwise healthy patients with single li ver metasta es 
located only in one hepatic lobe, no extrahepatic metastases, and have had their primary tumour already resected .1 
Chemotherapy i performed in patient with advanced colorectal cancer. The most commonly u ed agent i 5-
fluorouracil , which is usually admini stered with leucovorin , a reduced folate .11 This treatment has been fo und to 
reduce tumour ize by 50% or more in 20% of patients, and prolongs median surviva l from 6 months to 11 months. 11 
The mo t common ide effect are neutropenia and stomatiti s. 11 Chemotherapy also plays a ro le in palli ati on of 
metastatic disease, u ing newer agents such a irinotecan and oxaliplatin.3· 11 
Radiotherapy is used in rectal cancer, either pre- or post-operatively to decrease the risk of pelvic 
recurrence by 20-25~ .2 However, it doe not appear to prolong urvival; at best, it may increase survival by 10%.2•3 
Radiation therapy has not been found to be effective in treating primary colon cancer? 
Conclusion 
Colorectal cancer is a cancer that does have effec ti ve creening techniques to detect it in early or 
precancerous stages. A variety of screening options are avail able, with corresponding advantages and 
disadvantages. Clinicians need to be aware of the ensiti vity and specificity of screening test when discu sing the 
di fferent options with patients. Once colorectal cancer is diagno ed, management varies depending on the ite and 
stage of the cancer, ranging from surgery to chemotherapy to rad iation. 
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Zebra Files 
Rare complications of common presentations in family medicine: a review of Metastatic Basal Cell 
Carcinoma and Hypertension in Pregnancy secondary to Pheochromocytoma 
Tiffany Kwok, Meds 2010 
Badrinath Narayan, Meds2009 
The Zebra fil es secti on, with a definiti on of unusual and interesting case , at the surface 
seem to contradict thi i ue' theme of family medicine. However, it is important for 
family phy icians and generali sts to be aware of rare and serious complicati ons of 
relati vely benign and common conditi ons so they can refer accordingly. In this is ue 
our artic le will explore two rare complications of two di fferent common presentati ons in 
family medicine- metastatic basal cell carcinoma, and endocrine hypertension in 
pregnancy cau ed by pheochromocytoma. 
This article has been reviewed by Dr. Nithya Romani. 
PART I: METASTATIC BASAL CELL CARCINOMA 
Introduction 
Basal Cell Carcinoma (BCC) is the most common malignancy worldwide, with a lifetime risk of 30% in 
Caucasian, North American populati ons. It is generally an indolent kin tumour with low metastatic potential and 
high cure rates. However, consequences of metastas is are often deadly and it is important to be aware of this severe 
complication. 
Clinical Presentation 
There are 5 main clinical subtype of BCC: 
1) Nodular BCC- the most common variant presents as a firm , translucent papule or nodule with a mooth 
surface, te langiectas ia, and well -defined border . A cy tic vari ant i uncommon. 
2) U1cerating BCC- also known a rodent ulcer, presents as an ulceration on the skin with a rolled border, 
translucency, smooth surface , telangiectasia, cru ting. 
3) Morpheaform/Sclerosing BCC- resembling a superficial scar, white/yell ow waxy clerotic plaque with 
pepperish pigmentation. 
4) Superficial BCC- thin, erythematous plaque with telangiectasia and scaling. Usually multicentric. 
5) Pigmented BCC- A rare variant, pre ents with bl ack or brown macule uperimpo ed on features of nodul ar 
BCC. 
Most BCC' s occur a an isolated single lesion on the head and neck in light-skinned males over 40. Differential 
diagno is of BCC inc lude quamous cell carcinoma, actinic keratosis, sebaceous hyperplasia, dermatofibroma, 
superficial spreading and nodular melanoma, and melanocytic nevi, depending on its subtype. 
Table 1: Predisposing factors for BCC 
Skin phototypes I, II or albino with prolonged sun exposure1'2 
Hi tory of heavy un exposure in childhood 1 
X-ray therapy for facial acne2 
Inge tion of arsenic (Superficial multicentric BCC)I.2 
• 5 ImmunosuppressiOn 
Positive family hi tory of skin cancer' 
Genetic conditions (albinism, xeroderma pigmentosum, Bazex's syndrome, Gorlin's syndrome) 1 
BCC may be treated surgically or non-surgica lly. Surgical treatment includes electrode sication and 
curettage, cryosurgery, excision and Moh ' micrographic urgery. The latter is re erved for ca es in high ri sk ite 
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on the face , morphoeic and recurrent tumours. C ure rate for surgical treatment exceed 95 %: . N~n-sur~.i5ca l 
treatments are Jess effective and include radiati on, photodynamic therapy, and topical fluorouracil or muqUimod. 
Metastasis 
Metastasi is such a rare occurrence that some sources even state that BCC doe not metastasize . However, 
reported rate of meta tas i range between 0.0028 to 0.55% of all BCC' . Meta tati c BCC (MBCC) was fir t 
described in 1849 by Beadle whose 46-year old male patient had an ulcerating BCC on the face metastasizing to the 
submaxi llary lymph node.3 In 195 1, Latte et. al. described criteria for MBCC (Table 2): 
Table 2: Lattes' criteri a for MBCC3 
Primary tumour originated from the skin and not from mucou membrane or other gland 
Metastasis occurred to a distant site from the primary tumour and could not result from direct extension 
Both metastati c and primary tumours have identical histopathology 
Since 1849, there have since been onl y over 300 cases of MBCC reported . Many of the predi spo ing 
factor for MBCC are similar to those of BCC, commonly pre enting in light- kinned indi vidual s, males, and in the 
head and neck area. BCC' have been found to me ta ta ize through both hematogenou and lymphatic avenue , 
lymphati cs being more common. Common ites for meta ta is (in order of frequency) include lymph nodes, lung , 
bones, skin and parotid glands. In von Domarus e t. al. ' review of over half of the e ca e , patients first developed 
BCC at a median age o f 45, and later presented with MBCC at a median age of 59.4 Thi i hi gher than that of BCC, 
and pos ible explanations include inherent aggressiveness of earli er-presenting BCC. or older patients may not 
urvive to metastas is.3 Medi an time from start of BCC to progres ion to MBCC wa found to be 9- 11 years, but 
interval range from month to decades.3 Prognos is of MBCC is poor, with a medi an urvival of 8-14 month after 
its diagnosi , and a 5-year urviva l rate of 10%.3·4 
Table 3: BCC at high ri sk for metastasis3•4 
Located on head and neck 
Size >lOcm 
Deepl y penetrating tumours 
Perineural spread 
In vas ion o f blo d ves e ls 
Multiple recurrences in primary tumour site 
Mor heaform and adeno y. ti c ubty e 
Workup for pati ent with uspected MBCC con i t of hi tory and phy ical examination, concentrating on 
lymph nodes near the primary BCC. Helpful lab te. ts include CBC, li ver functi on, bone can, and CT scan of the 
chest, abdomen and pelvis. 4 
Because o f the rare nature and poor prognosi o f MBCC, there i not much evidence urrounding optimal 
treatment. In general, treatment i palliati ve and depe nd on the locati on o f meta tasi a we ll a the general health 
and age of the pati ent. ln case of local spread, surgery prov ide the be t progno i , wherea radiation therapy and 
chemotherapy with C i platin is best for genera li zed di ea e.~ 
Conclusion 
Basal cell carcinoma is an ex tremely c mmon malignancy that is ometime treated by family physicians 
due to ease o f treatment, however, knowledge o f it deadl y metastatic potentia l is crucial to prompt re ferral , 
treatment and poss ibl y better prognosis for the patient. 
PART II: HYPERTENSION CAUSED BY A PHEOCHROMOCYTOMA AND IT'S MANIFESTATION IN 
PREGNANCY 
Introduction 
Hypertension is a frequent complication o f pregnancy and may compromise fetal and maternal outcome. 
Hyperten ion may be pregnancy- induced, e . enti a! r econdary to endocrine di orders. Mo t cases o f endo rine 
hypertension are the con equence of adrenal disea es.3 In one ca e in the literature, a pregnant female who has been 
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suffering from persistent hypertension arri ves at her fa nlily phys ician complaining of a headache. T he pa ti ent is a 
recent immigrant to Canada and does not speak English very well. T he results of the test made during that vi it fi nd 
that the pa ti ent ha a conste ll ati on of negati ve sign and ymptoms: pers istent hypen en ion, hyperrenexia, edema, 
proteinuri a, o liguria, hyperuricenlia and thrombocytopeni a. T he fa nlily doctor uspects preec lampsia. However, in 
thi case the patient was eventually found to have a very rare conditi on ca lled a pheochromocytoma. 1 
The mo t hazardous form of endocrine hypertension during pregnancy is a pheochromocytoma because it 
may in volve paroxy mal arrhythmia and/or hypertension during labor. 3 It is therefore important that it be d iagnosed 
early during the pregnancy to reduce mortality and morbidity to the mother and the baby. D iagnosi i diffic ult 
however because a pregnant woman can present solely with chronic hyperten ion and headaches, which can lead 
one on the path to su pect preeclamp ia or e entia t hyperten ion. In the case tudy, as the author menti on. the 
wor ening headache and labile hyperten ion could also be attributed to stre s, cultural isolati on and med icati on. 1 
Natural History 
A pheochromocytoma is rare, found in about .01-. 1% of pati ent with hyperten ion in the general 
population. There are only about 200 ca e reported of it occurring in pregnancy.4 They are catecholanline 
secreting tumours of the adrenal medulla 's chromaffin cell s (of neural ere 1 origin and secreting epinephrine, 
norpeinephrine and dopanline ). They can occur at a ll ages in both sexes. but should e pecia lly be suspected in 
patient presenting with poorly controlled hypertension at less than 40 years of age. 
In pregnancy, the maternal mortality rate is 2-4% if tumour is diagnosed in the antenatal peri od , and I 4-
25% if diagnosed intrapartum or after delivery. 1 Fatal cri e can be caused by variou stimuli fro m anesthe ia to the 
mechanical effect of vigorous fe tal movement to the expulsive forces of vaginal deli very.4 Fetal mortality is 11 -
15% antenata lly, but 55 % if during labour or a fter deli very. 1 
Pathophysiology 
They are poradic in 90% of cases and inherited in 10%. They are a soc iated with ME N, MENnA and 
MEN1IB syndromes. 1 They are often described by the 10% rule : 10% ari se in a sociati on with fanlilia l syndrome , 
10% are ex tra-adrenal , 10% in sporadic cases are bilateral, 10% are multiple and 10% are malignant. Prognostic 
fac tor for a pheochromocytoma include stage, age, histology, and various chromosomal markers such as DNA 
ploidy, n-myc amplification, trk- a expre ion, 17q gain , 1p lo and te lomera e expres ion. 
Diagnosis 
Diagnosi is made by recogmzmg the e ffect of a hormonal nlilieu cau ed by excess catecholanline 
secreti on (a sympathetic response) as well as the re ulting producti on of various vasoacti ve peptides. A patient can 
present with a combination of hypertension, Headache, Hyperhydrosis (sweating flushing of the skin ), Hypomotility 
of gut (constipation), hyperglycenlia and hypermetabolism (tachycardi a, anxie ty,nau ea,palpitation ). 
AI o di stingui hing is postural hypotension and hypertension worsening in the supine positi on. 1 It can be 
u tained or paroxysmal, and there can be a drop in orthostati c blood pre sure. C ia ical symptom of 
pheochromocytoma can be reproduced by an abdonlinal massage in the postpartum period . 1 
A 24 hr urine screen for metabolites of catecholanlines(metanephrine , fractionated catecholanlines and 
vanillylmandelic acid) is the common creening te t. A pia ma screen can also be done for catecholanline or 
metanephrines. T wo normal test of plasma and urine catecholanlines can exclude a di agnosis. Te ts for tumor 
location are linlited to ultra ound and magnetic resonance scans in order to avoid maternal and fetal irradiation.3 
Differential 
Other conditions which increa e catecholamines include anxiety, pain , bl adder di tenti on, trauma and 
pressure on the tumor. Cardi omyopathy has been reported as a complicati on of a pheochromoctyoma in pregnancy. 
CHF can increase pl asma and urine metanephrine levels. 1 
Management 
The patient i managed by the family physician in tandem with constant ob tetrical monitorin o and a 
0 
prompt endocrinologist referra l. While re ferral to a surgeon for excision o f tumour is the de finiti ve cure, c linica ll y it 
i till controversial as to when it can be safely used' . Expert do agree however that diagnosis in later pregnancy is 
best handled with medical stabili zati on. 
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Alpha blockade should a lways be established before before ~- If ~-adrenerg i c blockade is attempted first 
to red uce blood pre sure by reducing heart rate and contractility, it will also result in the loss of vasodilation caused 
by ~2 receptors. There will be an increased alpha effec t that is unopposed by ~2, and will thus have further increased 
the blood pressure. The alpha blocker of choice is phenoxy-benzam.ine.4 
Conclusion 
A pheochromocytoma is a rare yet hazardous form of endocrine hypertension during pregnancy which a 
physician should be vigi lant for in patients with poorly controlled hypertension and a constellation of signs and 
symptoms which point to a adrenergic hormonal milieu. Medical stabilizati on, prompt referra l and consideratio n of 
surgery are the components of proper management. 
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Annular Papules: Making the Right Diagnosis 
Mohamed Alarakhia, Meds 2008 
Annular papules or pl aques are frequently encountered by Family Phys icians. Tinea 
corpori s is often the first entity that come to mind because it is common and it 
class ically pre ents with thj s morphology. However, there are o ther important djagnoses 
that need to be con idered . For example, granul oma annulare is characterized by 
erythematous or tle h-coloured pl aques with smooth borders and no scaling or vesicles. 
The les ion of nummul ar dermatiti s are coin shapped papules with central vesic les that 
expand and cau e a central clearing. Subacute cutaneous lupus erythematosus can 
present with bright red annul ar lesions with central regress ion and little caling. Fixed 
drug eruptions appear as we ll demarcated plaques that can develop central vesic les or 
bulla. This arti cle will review the e conditi ons. 
This article has been reviewed by Dr. Firas Al-Dhaher. 
Introduction 
Examining the morphology of skin lesions is critica l when worki ng towards a diagnosis. H owever, one 
must be care ful not to link a specific morphology with a s ingle entity. Annular papule or plaques are quite di stinct, 
but they can also be very deceptive. These ringed lesions immediate ly prompt both patients and physicians to think 
of "ringworm" or more correctly tinea corpori s. The term "ringworm" i a mi nomer from a time when such raised 
ringed lesions were be lieved to be caused by invasive worms. 1 The associati on between annular lesions and tinea 
corpori s can lead to a delay in the diagnosi and treatment of many of the other lesions that can present as annular 
papules or plaques (Tables 1 and 2). Thi s arti cle will review tinea corpori s, granuloma annulare, nununular 
dermatiti s, subacute cutaneous lupus erythematosus, and fi xed drug erupti on 
Differential Diagnosis of Annular Papules or Plaques 
Infections: Tinea Corpori s 
lnfl anunatory: Granuloma Annulare 
Dermatitis: Nummular 
Drugs: Fixed Drug Erupti on 
Autoinunune: Subacute C utaneous Lupu Erythemato us 
Table 1. The Differential Diagnosis of Annual Papules or Plaques. 
* note: The diffe rentia l di agnosis of annul ar les ions i vast. Onl y annul ar papule and plaques were reviewed in 
thi s arti c le and even these entiti es were limited to tho e deemed suita ble for an initi al differential diagno is. 
Images 
Images for the lesions presented in thi s arti c le (with the exception of nununular dermatiti s) can be viewed at: 
http://www.atl asdermatologico.com.br/ 
The pic ture number and names are indi cated be low: 
Tinea Corpori s 
5600 . Tinea Corpori s2 
5597. Tinea Corpori s l7 
Granul oma Annul are 
1771 . Granul oma Annulare I 
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1794. Granuloma Annul are6 
Nummul ar Dermatiti s 
http://www.lib.ui owa.ed u/hardin/md/pic tures22/dermnetleczema_nummularecz0530053.jpg 
Fixed Dru g Eruption 
1 628 . Fixed Erupti on 
Subacute C utaneous Lupus Erythematosus 
3 190. Lupu Erythemato u - ubacute Cutaneou Lupu rythematosu 2 
(le ion under latera l aspect of left eye) 
Tinea Corporis 
Tinea corpori s is the most common cause of annular le ion in adults. ' It is a dermatophyte infecti on that is 
commonl y caused by Trichophyton rubrum and Trichophyton tonsurans in the Uni ted States and Canada. 2 An 
indi vidual can be infected by contac t with infec ted persons, animal , or oil. 3 
There are o ften multiple erythematous scaly papule or plaque that have an _active border.45 They may 
gradually enlarge over time and pread centrifuga lly from the po int of kin invasion. Lesions may be a ociated 
wi th ve icle . There may al o be burning and pruritus . ~ The typ ical distribution include the trunk and extremi tie 
excluding the nail , palm , sole , and gro in .4•5 The diagno i is clinical and treatment i with topical antifungal uch 
a c lotrimazole, miconazole or terbinafi ne.3•5 If resi tant to topical therapy, systemic antifungals can be used .3 
Granuloma Annulare 
Granuloma Annulare is a common asymptomatic cutaneou condition o f unknown eti o logy. The le ions are 
erythematou or tl e h-colored non- caly papule .6 The papule. group together forming an annular arrangement. 6 In 
contra t to tinea corpori , there are no as ·ociated ve icle and the annular border i mooth with no scaling.' Lesions 
can be found anywhere on the body, and are most commonly een on the legs and the dor um of the hand and feet 7 
Often the palms, sole , and calp are pared. The diagnosis of gruanul oma annulare i c linical.6 A punch biopsy is 
done if there is any uncertainty about the di agno is.6 Becau e granuloma annulare i elf limited and re o lves 
pontaneou ly in more than 50~ of patient in two months to two years, no treatment in required. 7 However, 
patient often find the les ion di stressing; thus, for cosmetic purpose or in ca e where the condition i more 
chronic, topical glucocorticoid are the first line o f therapy. 7 Intrales ional corticosteroid inj ections, cryotherapy, and 
electrodesiccation are other options.6 Little evidence has been accumulated on the effi cacy of treatment option for 
di seminated granuloma annulare. Dap one, i otre tinoin , hydroxycholorquine, and PUV A (p oralen and ultrav io let 
A) have been used with some ucce in mall uncontrolled tudies and ca e report , but consultation wi th a 
Dermato logi t should be sought at thi stage.6 
Nummular Dermatitis 
Nummular dermatiti s i a di eminated eczema that is characteri zed by well demarcated coin- haped 
papule and plaques.8 Central ve icles may form , which then expand and cau e a central clearing.' The latter 
phenomenon results in an annul ar appearance.' The le ion can be assoc iated with pruritu , xeros i , and contact 
en itization (e.g. nickel, chromate, fragrance , etc.).5'8 Nurrunular dermatitis commonl y affect the ex tremitie and 
often fo llows a very ctyonic cour e. 1' 8 The diagnosis is clinical and the treatme nt i with medium to hi gh potency 
topical corticosteroid .) 
Fixed Drug Eruptions 
Fixed Drug Erupti ons (FOE) generally occur l -2 week after the fir t expo ure to a drug.5 Sub equentl y, 
le ion develop over the cour e of 24 hour .5 There are ca e report that dem n tra te FOE with most of the 
commonly used drug including ulfonamide , NSAID , barbituates, tetracyc lines, and carbemazepine.5· 9 One or a 
few round, harply demarcated, erythematou or pigmented plaque typica lly appear. They may became edematous 
or form vesicles or bulla. 10 The ve icle or bulla are often central giving the appearance of an annular lesion. In 
addition, an erosion can develop in the middle of the le ion.5 Le ions can occur anywhere in the body, but often 
favour the lips, face, hand , feet and genitalia.5' 9 They fade over several day often leav ing an area of 
hyperpigmentation .9 There i al o a variant of FDE that i non-pigmenting.11 When the cau alive druo is 
. b 
readmini tered the leswns reoccur exactly on the arne ites, which is a di tinguishing feature of FOE. 10 Additional 
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lesion may also appear on readm.in.i tra tion. 10 Diagnosis is based on hi story and patch or provocati on testwg. 
Topical applicati on of increas ing concentrati on of drug will illic it the reac tion in many pati ents. 12 Con! rolled oral 
exposure to the drug is attempted if topical testing is negati ve and the drug is still strongly uspec ted. The maw 
treatment is eliminati on o f the offending agent. 9 
Subacute Cutaneous Lupus Erythematosus 
Subacute cutaneou lupus erythematosus (SCLE) presents as either annul ar or psorias ifo rm 
3 • I. t4 
papulosquamous le ions.' The annular les ions are bright red with central regression and httle sea w g. 
Photosensiti vity is a significant component of SCLE. Thus lesions commonly appear on the ex tensor surface of the 
t3 L · 
arm , dorsal surface of the hand , upper bac k, the V -neck area o f the upper che t, and the houlders. e JOn 
re o lve with light atrophy (no earring) and hypopigmentation.13 Di agnosi is ba ed on clinical findings and 
confirmed by hi to logy and immunopathology.13 Approx.i mately 50% o f pati ents with SCLE will ati sfy four or 
more of the American Rheumati sm A soc iati on's criteria for systern.i c lupus erythematosus.' Using 
immunopathological te ting, immunoglobulin and/or complement components can be shown to fo rm a granular 
band- like array at the dermal-epidem1al juncti on in 60% of SCLE pati ents. 15 F urthermore , a di tincti ve "du t-like" 
pattern o f lgG depo iti on overl ying epidermal ba al ce ll s and cell just below the dermal-epidermal junc tion was 
reported t be an frequent marker for SCLE le ions. 15 In terms of sero logy, 70 % of these pati ent are ANA po itive, 
while 63 o/t have Ro antibodie . 14• 16 The first tep in treatment is avo idance o f exposure to unlight by using 
un creens or phy ical barri ers. Topical or lntralesional corti costeroid , tacrolimus, or pimecrolimus would be the 
nex t step.17·18 Most pati ents will go on to require some fo rm of syste rn.i c therapy. 19 Approximate ly 75 % of SCLE 
pati ents res~ond to single agent or combinati on am.inoquinoline therapy (hydroxychl oroquine, chloroquine , 
quinicrine). 1 For those who fa il antimalari a l therapy o ther options inc lude dap one, thalidom.ide, c lofazarn.ine, gold 
fo rmul ati on , and methotrexate. 13 
Conclusion 
Formul ating a good differential di agno i of annul ar papules and plaque is an important tep in reducing 
the tendency to labe l all annular lesion a " ringworm". It will he lp fac ilitate the appropriate in vestigations and 
management of the e varied conditions. 
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Feature Article 
Preventive Care Strategies in the Management of Systemic Lupus Erythematosus 
Tiffany Kwok, Meds 2010 
Stephen Chihrin, Meds 2008 
Sy temic Lupus Erythematosus (SLE) is one of the mo t common yet complex 
autoimmune connecti ve ti ssue disease . The c linical picture painted by SLE is broad , 
affec ting musculo keletal , ski n, cardi ovascular, renal and centra l nervous system , and 
thu pre ents a challenge for any physic ian to manage. One of the most important roles 
for a family phy ician in the care of this pati ent i to focu on preventi ve measures to 
minimize compli cation from SLE thereby improv ing quality of life. Thi article aims 
to review the common presentations and complications arising from SLE and the 
corresponding po sibilities for a preventi ve care approach. 
This article has been reviewed by Dr. George Kim. 
Introduction 
Systemic lupus erythematosu (SLE) is a complex auto immune connecti ve ti sue di order not uncommonly 
encountered in general practi ce. SLE ha a prevalence of nearl y 30 per 100,000 pati ents, and is significant for its 
frequency in younger female , occurring nearly nine time a often in women, with onset most often during the 2"d 
to 4th decade of life. 1.2 A patient with SLE poses numerous long- term challenge to the primary care physician , with 
potenti al for acute life threatening multi-system organ di ea e a well a chronic debilitation resulting direc tl y from 
the disease itse lf or secondary to medical management. The predi po ing and precipitating factors underlying SLE 
are not well under tood, but are be lieved to inc lude genetic and environmental trigger re ulting in dysregul ation of 
both innate and adapti ve inm1Une mechani m a well as impaired c learance of immunogenic complexes inc luding 
apoptotic cell s. 3·4 The diffi culty in understanding the e mechani m , their interacti on, and their own e tiologies 
currently preclude primary prevention. A such, SLE mu t be aggre ively managed following di agnosis to 
minimi ze ongoing complicati on ri sk. Thi s paper aim to address a number of area in which preventive medicine 
can greatl y improve the quality o f life o f indi vidual with SLE, and potentially reduce long-term morbidity. 
Diagnosis 
The American Co ll e~e of Rheumatology ha established di agno tic criteria, quite familiar to the medical 
tudent, as shown in Table 1. Intended for re earch c ia ifi cation, the e criteri a provide an overview of potential 
signs and ymptom but h uld not be relied upon for indi vidual diagno i . The complexi ty of these criteria 
illustrates the considerable variability of SLE and the difficulty comm nl y encountered in reaching a diagnosi . In 
fact, it ha bee11 . uggested that mo t pati ent receive a di agno i nearly five years following initial onset of 
ymptom .6 
The most commo n initial manife Lati ons inc lude mal aise, fatigue, nau ea and anorexia. 2 A low grade fever , 
photo en iti ve rashes, pleuritic che t pain , complaint of xerostomia or xeropthalmia, hair lo s, or sudde n and 
persi tent arthralgia may a l o appear early in the disea e and are more conunonl y the reason for initial pre entation 
to the genera l practiti oner.2 Selec t laboratory diagnosis may be initiated prior to pecialis t referral and can 
demonstrate pos iti ve anti -nuclear antibodie , as well as antibodie to double- tranded DNA. 1 Classically, ESR 
appears elevated in the absence of an e levated CRP. Additiona l laboratory inve ligation completed during initial 
work up may also reveal anemia or signs of li ver or kidney impairment. Additi onal antibody screens, genera lly 
initi ated by a rheumatologist, may inc lude anti-ENA, Ro, La, RNP, or Sm. 1•2 
Principles of Management 
Management of SLE is generally initi ated by a spec ia li t and then continued cooperatively be tween 
pecialist and the primary care provider, and in no n life-threatening ca e consist primarily of symptomatic 
management. To this purpose, analge ic and antimalaria ls are frequently employed. Acetaminophen has shown 
~odest effec tivenes~ in _controllin ~ pain , while ~n.ti~a l arial such a . hydroxychloroquine are uccessful in reducing 
tnflammatJ on re ul~tng tn arthral g 1 ~ and dennalltJ . Thes_e therap1es ~ave also been associated with significantly 
lower level of pati ent reported faLJgue and frequency of d1 ea e flares. It hould be noted that non- teroida l anti -
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inflammatory drug (NSAIDs) are re latively contraindicated in the treatment of SLE secondary to the numerous 
complicati ons of SLE that may be exacerbated by NSAID therapy, inc luding acce lerated athero c lero is, nephriti , 
and a ep tic meningiti .2•6 
Life threateni ng flare of SLE, including acute lupus nephriti s, often require inpat ient initiation of high 
dose glucocorticoids in combinati on with immunosuppre sive agent inc lud ing cyc lophospharrude or 
mycophenolate.2 Due to the difficulty in preventing fl ares pharmacologica lly, and the significant comorbiditie 
associated with major fl ares and their treatment, there exists significant potential for reduction in long-term 
morbidity and mortality through preventive care. 
Preventive Care 
Many complication may ari e from a fl are of SLE. For the purpose of thi article, we will discuss 
trategies which may prevent or delay the onset of these complicati ons. 
Musculoskeletal 
Joint pai n i an ex tremely conunon and physically debilitating complication of SLE. Tendernes and 
inflammation are found in a synunetric, nonero ive polyarthriti s commonl y presenting in proximal interphalangeal 
and metacarpophalangeal joints, as well a wrists and knees.6 Care must be taken to rrunirruze tre s placed on the 
joints e pecially during heavy lifting acti vitie . Minimizing j oint stress may also improve fat igue, which has al o 
been pos tulated to trigger fl are-up of SLE in ome. Additionally, exercise may reduce sti ffness and increase 
muscle strength. 7 
Osteoporosis and o teopenia are reported in a many a 46% of patients. Deficit in bone mineral density is 
said to be a result of both disease mani fes tations (fatigue, j oi nt and muscle inflammati on and pain can reduce 
mobility and impair weight bearing acti vity for a given bone mass) and prolonged corticos teroid use. 
Cortico teroids are commonl y used in the treatment of SLE and increase the ri sk of osteoporosis by di sturbing 
calci um homeostasis, decreasing bone formation , and decrea ing circulation of gonadotroph .8 Ramsey-Goldman et 
al. have shown a positive association in women between those with SLE and increased bone fracture ri sk. 9 
Fortunately, regular exercise (a rrunimum of 40 rrunutes of aerobic acti vity four time a week) ha been hown to be 
protecti ve of bone rruneral density Jo .7 Other preventive options include smoki ng ces ation, moderate 
con umption of alcohol, adequate intake of dietary calcium and vitarrun D, and measures to prevent falls in the 
elderl y. Finally, dosing of corticosteroids hould be constantly monitored and evaluated to minirruze dose whenever 
po ible.8 
Skin 
Photo ensiti ve skin ra hes such as discoid lesions and malar rash affect up to 20% of patient with SLE and 
may be earring and disfi guring.6 Ultraviolet radiation i po tul ated to trigger SLE fl are by damaging cellular 
material, most notably nucleic acid , and degrading them into inununogenic complexe .3•4 Patient hould be 
counseled in sun avoidance and sunscreen usage, as this will rrunirruze rashe and potentially reduce the freq uency 
and everity of subsequent fl ares. 1 
Renal 
Lupu nephriti s i a serious consequence of SLE, with ymptoms ranging fro m hypertension and 
protei nuria to renal failure. Although there are no known mea ures to acti vely prevent the on et of lupus nephriti , 
frequent monitoring of creatinine and urine protein and cellular ca ts can alert the c linician to renal disea e earlier in 
its progression. 1 Strict avo idance of NSAIDs and careful consideration prior to use of any other potentially 
nephrotoxic medication is required in all patients with SLEY 
Cardiovascular 
Cardiovascular complications such as atherosclersosi , thromboembolic events, pulmonary hypertension, 
pericarditi s and systolic murmurs occur at higher rates in SLE patient than the general population.10 Currentl y, 
ischerruc heart disea e is a leading cause of death in SLE patient , with mean age of first myocardial in farc tion at 49 
years (20 years before that for the general population). Additionally, Esdaile et. al. fo und that young patient with 
SLE ha a 7-10 times greater ri sk of developing cardiovascular disease than the Frarrungham ri k factor esti mate 
dictate . 11 As with the general population, exerci e is shown to improve cardi ovascular outcome in SLE patients. 
Risk factors contributing to development of ischerrua such a hypertension, hyperlipidemia, di abetes mellitus and 
sedentary lifestyle, may all in part be addressed by exercise. 7 Other preventi ve mea ures uch as smoki ng ce sati on, 
nutrition coun eling to decrea e lipids and chole terol in the diet, di abetes education, and med ications including 
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low-do e a pirin and a stalin may he lp prevent cardiova cular complication .10•12 Additionally, antimalarial agents 
such as hydroxychloroquine typica lly used to combat joint and skin manifestations of SLE have also been shown to 
reduce LDL-cholesterol, triglyceride levels and thromboembolic event , and improve insulin resistance and 
glycemic contro l. 12 
Central Nen ,ous Svstem 
CNS cha~ge affect 1 2-59~ of patient with SLE and m t commonly present a intractable headache , 
memory and reasoning difficulties, se izure and troke. 1 No preventi ve strategies for headache , memory or 
cogniti ve diffi culti es have yet been reported . However, seizures and troke due to thromboembo lic events may 
benefit from imilar cardi ovascular preventive trategies as di cussed above. 
Fatigue in SLE i a lso extremely common, affecting up to 80% of patients, yet is difficult to manage, oft en 
per i ting despite di sease tl are remiss ion.1•6 Althoug h the mechani sm is largely unknown, sleep interrupti ons are 
thought to ac t as a mediator through which SLE increase fatigue. Exerci e has been shown to help wi th both 
fatigue and sleep disturbances, as it increases capacity of the oxidati ve metabolic pathway to supply energy. Studie 
have hown positi ve as ociati on between exerc i e and higher sleep quality, increased pati ent reported energy and 
overall well -being. 7 
Pregnancy 
Pregnant women with SLE are at increased ri sk for earl y lo of pregnancy, feta l death , pre-eclampsia, 
preterrn deli very, and increased maternal thrombo is. 1 Regular fo llow-up with a physician to monitor blood lupu 
anticoagul ant and anticardiolipin antibody level may minimi ze ri k during pregnancy, e pecially mi carriage. 
Furthermore, a recent Cochrane rev iew by Empson eL al. has shown that unfractionated heparin and low-do e 
aspirin he lp reduce pregnancy loss by 54% in tho e with high level of lupu anticoagulant and anticardi olipin 
antibodie .13 
Table 1: Diagnostic Criteria for Sy temic Lupus Erythematosus. A pati ent demon trating four or more of the 




Oral or Nasopharyngeal Ulcers 
Hematologic Disorders- non-iatrogenic leukopenia, lymphopenia, thrombocytopeni a 
Serositis- pleuriti s or peri carditi s 
Arthritis- nonerosive in volvement of 2 of more peripheral joints 
Renal Disease- 3+ prote in or cellular casts 
Neurologic Di sorder- seizure, psychosis 
Antin uclear Antibodies 
Immunologic Disorders- including anti -dsDNA, anti phospholipid Ab, anti -Sm 
Conclusion 
Systemic lupus erythematosus pre ents a number of ignifi cant management challenge to the general 
practiti oner and rheumatologi. t alike. The age o f on et and p tentia l for con iderable morbidity and morta lity in a 
potenti all y very healthy pati ent otherwi e requires tri ct vigilance to addre preventive care . trategies. As SLE 
pre ent and continues to develop a a multi - y te rn di ease, it i useful to review each sy tern , it complicati on , 
and potenti al for unrea li zed preventi ve care at each foll ow up visit Thi , in conj unction with appropriate treatment 
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Feature Article 
Patient Centered Approach to Primary Prevention (PCAPP) 
Adeel Mahmood, Meds 2009 
As Tommy Douglas helped usher in Canada 's Medicare system in 1967, it marked a 
new era in Canadian health care and one that went onto become one of defining factors 
of Canadian society. Most Canadians cherish the Public health care system and consider 
it an extremely important part of Canadian ociety. However, for as long as the system 
has been in place there have been que ti ons about the viability of the system and forty 
years since its inception, we stand at a critical juncture in thjs seerrungly never ending 
debate. There is no doubt in that we as Canadians must continue to strive towards 
makj ng our system better so that we can stand firm on the core values of the Canada 
Health Act. In this essay, I aim going to uggest a People centered approach to primary 
prevention (PCAPP). Thi s i a group based approach to helping patients be better 
advocate of their own health . I believe that this program can help improve the quality 
of pati ent care and be an economjcally feasible approach to Primary prevention. This is 
defi nite ly not a complete solution to the challenges faced by the health care system. 
However, as the proverb goes: Little drops of water, little drops of sand, make the 
rrughty ocean and the rrughty land . This brief essay only proposes a step forward in 
reaching our goal of being a more pati ent centered health care system. 
This article has been reviewed by Dr. David Rosen. 
The Backdrop 
Before I go onto discuss my proposal in any great length , a little bit of hjstorical context wi ll be helpful. 
The topic of health care has been studied extensive ly and some even go on to say that it has been studied to death. 
There ha been a large in vestment of money, time and resources to find ways in whjch our system can be improved . 
Major reviews such as the Mazankowskj report, the Senate report and the Romanow report have made everal 
suggestions to improve the health care system and target issues such as ; increas ing funding , decreasing wait times, 
providing lirruted pharmacare, and a public v . a pri vate sy te rn. The e are obviou ly very critica l issues and are 
being addressed extensively. My essay, however, is ju t going to focus on an aspec t of our health system that I 
believe can have a great impact on the health of Canadi ans and the sustainability of our health care system. 
The push towards prevention 
I propose the idea of a more pati ent centered approach to Medjci ne where pati ents wi ll be empowered by 
more knowledge about their own health . Although thi i by no means a new concept, it is one that is often side 
lined as we face other challenges in hea lth care today . However, by educating patient about various illnesse and 
promoting an environment of healthy li ving we may be able to prevent many di eases and create better outcomes. 
Thjs will have an even greater impact in the next few years as our population becomes demographically older. The 
focus on di sease prevention can go a long way in making our Health care system better and stronger. 
Reali zing the fact that we have been reacting to pati ent illne s and di seases, rather than promoting 
prevention o f disea e, there has been a recent push to be more proactive in primary prevention and promotion of 
healthy living. The most important way that this can be accomplished is through patient education. Thi s is an 
enormous challenge in the ever-changing culture of medicine and becomes even more significant in a multicultural 
nati on like ours. Canad ians come from a diverse background of experiences and beliefs about healthy li vino 
o • 
therefore, any approach to health promotion must keep thi in mjnd . 
Many initi atives have been taken to increase pati ent awareness regarding common illne ses. The CTFPHC 
(Canadian Task Force on Preventive Health Care) and the IYH (It' s Your Health ) are two such initiatives. It' Your 
Health (IYH), for example, is a j oint publication produced by Health Canada (HC) and the Public Health Agency of 
Canada (PHAC) that provides information on a wide range of health and safety i sues. Other avenue of health 
promotion have been hundreds of pamphlets available on various topics, waiting room po ter and even television 
-42- UWOMJ 77(1 ) 2008 
commercial for the most pre sing health issues. Even though these are noble initi ati ves, the que ti on we must ask i 
whether the e are enough to accompli h the fi nal goa l. 
The need for a better approach 
We are moving toward a c ulture of "e lec tronic medicine" where people arc able to ga in a lot of 
information through online resources. Excellent webs ites have been crea ted to prov ide patients wi th more 
information regarding common health issues. However, for every good re ource, there are . everal others which 
provide mi sinformati on. We can also not as ume that most people will be expo ed to the informati on online and 
even if they are, whether it will provide them with the correc t and proven advice. Simil arl y, Health Canada ha 
created many pamphlets and document to promote healthy li ving and provide infonnati on regarding di sea. es. 
However, imply handing the m out does not mean that they will be read or even under tood by the majority of 
people. I believe that thi s is where our first line of de fen e, the primary care phy ic ian, has an ex tremely important 
ro le to play. 
Patient are quite recepti ve to the informati on provided to them by their Famil y Phys icians and they respect 
them a medica l experts. Primary care phy ic ian also have the unique opportunity of developing strong and trusting 
relati onship with their patients over a peri od o f years. Thi , coupled with the fac t that mo t people go to the ir 
Family Physicians for routine health check-ups, make the m the fir t and mo t important line of de fen. e fo r 
preventi on and early detec tion of illnesses. There is no doubt that part of the ro le of a Famil y Phy ician i to be a 
health advocate and an educator f r the patie nts. However, this become very diffic ult knowing the c urre nt shortages 
of Family Physician and the overwhelming work load being faced by many of them. The shortage of Family 
Physicians is not lirnited to rural area or mall c itie ; it i a problem that span aero many of the maj or c ities of 
the Country a well. It i certainly unfortunate, but it seems that the foc us has turned away from qua lity toward 
quantity. 
Yet thi is not the fault o f the primary care phy i ians, who mu t be commended for ab orbing a big part of 
this health cri si and taking on the re ponsibility of minimi zing it effects on patie nts. However, th is hi gh demand 
makes it difficult to educate patients about their health and illnesses. A recent urvey by the College of Famil y 
Physicians fo und that when on-call hours were included, family doctors typica ll y work between 70 and 80 hours per 
week. It is not difficult to imagine that this pres ure of time and the quantity of patients has an effect on the amount 
of time that can be pent talking to patient about common health care topic . A comprehensive li st of uch topics 
would be too long, but they include common things uch as: Exercise, diet and nutriti on, healthy li ving, Pregnancy, 
creening exam and their importance, e ffect o f moking, di abetes, hypertension, ri sks of STD , u e contracepti ve , 
well -baby care, effects of alcohol abuse and many more. Again, I have ju t li sted a few topic to give an idea of the 
type of things patients can be given more educati on about. 
A possible solution .... PCAPP 
Keeping in mind the limited time and resource in the hands of the family physicians and the enormous 
ta k of patient education, I make the suggesti on of a group ba ed approach to patient educati on which I call the 
People centered approach to primary preventi on (PCAPP) . The proposal is for small group se ions conducted by a 
family physician for tho e people in their practice who may be interested in the topic . Thi approach allows the 
physician to provide more detailed information about a particular topic and al o answer the que ti ons o f the patients 
in that group. The group can meet for a ses. ion of about Y2- l hour and the phy ician would be allowed to bill for the 
services he or she provides. This i a lso economicall y fea ible a a greater number of patie nt will be targeted in a 
small amount of time. Let me elaborate on thi s a little more using the example of hyperten ion. 
Let u assume that Dr. John i a fa mil y physician with a busy prac tice of 1500 patients. There is no doubt 
that several of his patients will have hypertension (which i the most common reason for visits to a fa mil y phy ic ian 
and a disease effec ting up to 22% of Canadians) . Dr. John may set up a ·· Living with hypertension " ta lk for a group 
of interested patients for an hour on a weekday evening. The talk will target not only tho e patie nts who have 
hyperten ion, but it can also be geared towards those who have borderline high blood pres ure. The patie nts will be 
more receptive to a session where they will be getting important informati on from omeone whom they trust and 
who has been providing them with care. 
Dr. John may .di scu s impo~tant i ue as ociated with hypertension, including preventi on, management, 
ide effe~ts of med1 cat10n, an? the Importance of exerci e a.nd diet. The goal will be to provide simpli sti c, yet 
valuable mformat10n to the pa~1ent so that they become more mformed about their conditi on and can Jearn to better 
manage it them el ves. The pat1ents can also ask any questions they may have about hyperten ion. It also provides an 
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avenue for further di scu ion that the pati e nt can have with Dr. John in a more confide ntial and one to one etting. 
This, in brie f, is the type o f approach that I be lie ve can go a long way in impacting patie nt health. Dr. John Will be 
remunerated for this talk and it will be billed to the provinc ial nl.ini stry o f health . This will be cost effecti ve becau e 
in V2- l hr the physic ian will be able to target 6-8 patients and greatl y influence their knowledge about a health topi C. 
Thi wa obviously a simpli ti c explanation of the pl an itse lf and it desired results. Some people may 
wonder why such a group based approach may he lp when we already have pamphlets, information docume nts a nd 
other re ource available for pati ents. As I have menti oned prev iously, the e docume nts most certainly exist, but can 
be of no ub titute for the informati on prov ided by Fanl.il y Physic ian . The docume nts may not be understood , if 
read at a ll , because pati ents often take the word of their doc tors in whatever they are being prescribed or to ld to do. 
The goa l of thi proposal to promote a more pati e nt centered approach to preventi on and earl y detection of disease. 
It may all eem g od o far , but I am in no position to c laim that there are no challenge with thi s approach. 
The challenges with PCAPP and how they can be overcome 
The firs t challe nge I ee in the implementa ti on of uch a plan is the willingne s of Fanl.il y Physicians to hop 
on board with uch a proposal. After a ll , they will be front and centre in this mall groups approach to pati e nt 
centered preventati ve care. As I have mentioned above, phys ic ian a lready fee l they are be ing overworked due to 
increa ed pati ent load. T he question then becomes how they will buy into uch an approach. I think the soluti on to 
thi s i two-pronged. First, phys ic ians must be an acti ve part in the developme nt of uch a program and secondl y, 
they should fee l that their e fforts a nd time will be re munerated well. The better the physicia ns fee l about the 
program and its outcomes for them and the ir patients, the greater the po ibility of success. The nex t importa nt issue 
the n become that o f funding. 
T he funding for thi s proposal should come from the nl.ini try o f health to which the Fanl.il y physician ' bill 
fo r the ir service . This will be no differe nt than a pati e nt con ult, except that it will be much more thorough, more 
producti ve and econonl.i call y feasible a a greater number o f pa ti ent will be targeted in a mall period of time. The 
Provincial nl.ini stri es of health can get the funding for the program from the federal government. Again , fund s that 
are be ing u ed in other areas o f primary preve ntion can be used t o ff e t ome of the co t of starting up suc h a 
program. Again, benefits of thi s project will certainl y outweigh the costs to the ystem. A greater challenge than thi s 
may be that o f c reating a standardized program. 
Although there will be fl exi bility in how the phy ician conduct the e group se ions, it will be he lpful to 
have ome tandardi zed features. The de igning of a standard module would require input fro m fanl.il y phy ician 
from a varie ty of practice . T he challenge in thi s could be co-ordinati on and collaboration of the many personne l 
who may be in volved with such a large ini tia ti ve. However. I fee l that thi i ue can be ea il y re olved by 
de ignating a body of respected physician who can come up with a imple standardi zed approach to these group 
ession , outlining the ir goa ls and objec ti ves. It will a lso be he lpful if the nl.ini stry of health provide all physic ians 
with the ma in objecti ves for a parti cul ar to pic and any handout that the pati e nt hould receive. T hi s task will no t be 
very di ffi cult as there is a lot o f information and re ources a lready cr ated by Health Canada. Reading the propo a! 
so far , one must ce rtainl y wonder about the poss ible investme nt o f time that thi s project will take. 
A major criti c ism o f the project may be that o f the amount of re ource needed , primaril y time and space. 
However, as I have outlined before, reaching out to a large number o f pati e nt in a hort period of time i the 
strength of th is project. There is no doubt that the phy ic ian may have ome di ffi c ulty cheduling a time convenie nt 
for them. e lve and the pati e nts, but I think thi s is a minor hurdle . Sinl.ilar to thi s i sue is that o f pace avail ability, 
because 6-8 people will require m re pace than a sta ndard exanl.ining room and since most clinics do n' t have a 
large common room available, the be t option eem to be an e mpty waiting room. The issue of timing and pace 
can be easil y re o lved if the fa nl.il y physician book a half hour to an ho ur after a day' c linic (i.e. the c linic hours 
can be reduced by one hour to accommodate the pati e nts). The tinl.ing will uit mo t pa ti e nt and the wa iting room 
will be ava il able to conduct these sessions. Rea li zing that these ses ions will be weekl y or bi -weekl y and both the 
pati ents and the phys ician will get rewarded for the ir time (the pati e nt with valuable information a nd the 
physicians with re munera ti on), thi s does not seem to present a signifi cant challe nge in going ahead with thi s 
program. 
So far in thi s essay, I have not di c ussed in a ny de ta il the pati e nt ' perspecti ve in my proposa l. The two 
most important c ha lle nge. I ee from the patie nt 's perspecti ve are interest and confide ntia lity. It nl.i ght initi ally be a 
cha lle nge to get enough pati ent interest in the new program. Thi s issue can be tackled by waiting room po te rs a nd 
recommendation made by the farn.il y physicians or other taff me mber . The parti cipation will be comple te ly 
vo luntary and I think that pa ti e nt. will be plea ed to get more informati on about conunon health topics a nd 
management of di sea es. I think pati ent interest will vary from topic to to pic , but in genera l patients will be 
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recepti ve to a group ba ed approach to learning abo ut common health i ues. PCAPP will a l o a ll ow patient to gain 
greater knowledge a they may ge t an wers to que ti on they may feel intimidated to a k them e lve . T he econd 
is ue, and in my opinion the biggest cha lle nge to this program, will be tha t of o nfi de nti a lity. 
Confi dentia lity is an important aspec t o f proper medica l care and at no po int ho uld any pa ti e nt 's confidenti a lity and 
afe ty be jeopardized. Thi can be a poss ible cha llenge for top ic uch as cancer or ex ually transmj ued d isea e , 
where the pati ent may not want others to make a sumpti on about them or they may fee l inti mjdated t allend . 
However, by de igning the group se ions around imple and le s cultural or ocia ll y sen iti ve topics, thi cha llenge 
can be ea ily overcome. Di cu ion uch as healthy li ving, proper exerci ing, nutriti on. hypertension, pregnancy, 
well-baby care e tc . do not po e a ignificant challenge in thi area. If patient are properl y infom1ed about the 
tructure and purpo e of the se s ion , it wi ll further reduce any i ue regard ing breach o f confidenti ali ty . Fi na ll y, 
the p rogram i 100% voluntary and n pati nt will be a ked to parti c ipate with utth ir approval. 
Conclusion 
It i aid that a ll that glitters may not be gold, but unles we look carefull y how can we rea lly know? 
There fore, to asses the prac ti cality and bene fit s fro m the proposed program can be assessed more thoroughl y if a 
pilot tudy i do ne. T his i the hope in which the author ha written thi propo at. The pilot study hould in volve 
everal willing farruly phy ic ian , from a varying range o f prac tice type , who will run these 3-4 group session to 
a ess the overa ll effec ti venes o f thi group ba ed approach to preventati ve care. T he a pee l. that would need to be 
a e ed are: u e of time and re ource , pati ent intere t, phy ic ian' review of the es io n and the associated co ts . 
Most o f the e can be tudied quite ea il y and the pati ent 's viewpo int can be tudied through a que ti onnaire. A pi lot 
tudy will really help to gage the trengths and weakne ses of thi proposal and if it has any po sible ro le in the 
future of our health care y tem. 
The CAPCH ha done a great job of timulating tho ught and bringing out idea that may potenti ally he lp 
our great health care system. I am a firm believer in the fund amental values that make up the Canadian Health care 
y tem, but in our pa ion we cannot forget that there i till much room for improvement and we, as a people, mu t 
fi nd avenue to overcome the challenges facing the ystem. The People centered approach to primary preventio n 
(PCAPP) i a humble uggestion which may be a building towards a stro nger and more viable health care sy te m. 
By providing patient with infom1ati on about common health care topics we can empower them to make better 
choice and promote healthy li ving. Critical analy is and further inve ligati ons about PCAPP may yie ld greater 
in ight into ways that people can be more informed abo ut their health . I end with the wise words of T ommy 
Dougla "M y friends, watch out for the little fe ll ow with an idea". 
UWOMJ 77(1) 2008 
-45 -
Feature Article 
Pharmacologic Considerations in an Elderly Population 
Wendy Ng, Meds 2009 
Usually, elderl y pati ents have more ongoing health concern than younger 
patient . To date, there have been few reviews that examine the benefit and challenges 
to pre ribing common medi c ine for a geriatri c p pulati on. Overall , NSAID , 
anticholinergics, neuroleptics and benzodi azepine have seri ous side effects that are 
more often manife ted in the e lderl y. Based upon the increased danger of 
pharmacologic ad ver e events in the older population, careful con ideration of the 
benefits and ri ks of the e medicati ons i e ential. It remains useful for c linician to 
consider afer alternati ves when writing prescriptions. 
This article has been reviewed by Dr. John Greenaway. 
In general, elderl y pati ents have both chronic and multiple diseases. Consequentl y, polypharmacy is a maj or 
factor in the prevalence of adverse drug reaction , which increa e in inc idence with pati ent age. In addition, e lderly 
patients have poorer homeostati c re ponses to physiologic challenges. A variable rate of declining organ and ti sue 
functi on among di fferent e lderly indi viduals further complicates attempts at predicting patient re ponse to 
pham1acologic therapy. Finally, with poorer compli ance to drug regiments, due to the complex itie of timing do e 
of many drug with different do ing chedules, sorting out pham1acology for elderly pati ents can be a cha llenge. 
In both male and female , the proporti on of total body weight as fat increa e with age. Fat i loca li zed to 
the middle and upper b dy region a we age. In women, there i an additional po tmenopau a l acceleration of the 
fat di stributi on trend. Body fat tend to accumulate within organ . After a plateau in rising fat proportions at 
approximately the sixth decade of life, a reduction in the amount of body fat follows in even older ages .1 
Body water as a percentage of total body weight dec lines with increa ing age. Furthem1ore, organ function 
tends to decrease with increasing age. Kidney glomerular filtrati on decrea e , a measured by creatinine clearance. 
At the ame time, serum creatinine concentration may not appear e levated, despite renal impairment, due to the 
decrease in serum creatinine concentrati on from lower levels of muscle ma as we age. In additi on, li ver ize a a 
proportion of body weight decrea e , leading to decreased total hepatic blood flow and poorer e limi nation of many 
drug from the body, parti cul arl y lipophilic drugs that have a hi gh hepatic ex traction ratio. Cardiac output decreases, 
which may be due to a combination of sedentary life tyle, progre ive ti ssue degeneration with age, or di ease. 
Blood perfusion o f ites of body drug e liminati on can be inadequate in cardiac failure. With a decrea ed 
baroreceptor refl ex, a. well , o lder pati ents are at greater ri k o f orthostati c hypotension.1 
Ba ed on the e complex interaction and a multitude of fac tors, pharmacology for e lderl y patients requires 
extra cons iderati on. The benefits and ide effect of NSAJD (non- teroida l anti-inflammatory drugs), 
anticholinergic drug , neuroleptic and benzodi azepine merit di cu sion, a the ir uses have important implications 
in thi s popul ati on of lder pati ent . 
NSAIDs (Non-steroidal anti-inflammatory drugs) 
NSAIDs (non- teroida l anti -inflammatory drugs) act by inhibiting the cyc looxygenase required for 
conversi n of arachidonic acid to endoperox ide intermediates (PGG2 and PGH2). Thi leads to antipyretic, 
ana lgesic and plate let-inhibitory effec ts. There are also effects on rheumatic, infl ammatory and immunological 
processes, as well as on acute gout. This cycl oxygenase inhibition is either readily or lowly rever ible , unlike that 
of acetylsa licy lic ac id.2 
Side effects o f NSAJD use include agranulocytosi , which i not een with alicylate use. A with a licylate 
use, NSAID cause gastri c muco al damage because they are weak organic acids, and inhibit prostaglandin ynthe is 
and accumulate intrace llul arl y due to the ac idity of the gastri c lumen. Thi is re lated to nonselec tive inhibiti on of 
both COX- 1 and COX-2 isoenzymes in vo lved in prostaglandin synthe is, where COX-1 generate pro tano id 
required fo r the maintenance of ga trointestina l mucosa and plate let aggregation, whereas COX-2 i required for 
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generating prostag landins that modify inn ammati on and pain . Ga tric bleed , anemia, epiga tric pain , hemate mesis, 
dy pepsia, ulcerati ve e ophagiti and ul cerati on and perforati on of the gas trointestinal system have a ll bee n reported 
with NSAID use. Pepti c ulcer di ea e is more igni fi cant in the e lderl y due to the higher prevalence f Helicobacter 
pylori and their more common u e of NSAIDs, compared to the ir younger counterparts' use of NSAIDs. 
In addition, the ynthes is o f thromboxanc A2 which is deri ved from cyc li c endoperoxides PGG2 and PGH2 
from arachidonic ac id by cyc looxygena e i reversibl y inhibited , such that pl ate lets may fa il to aggregate. 
Pro tacycl in (PGI2), whi ch oppo e pla tele t aggregati on, may be inhibited by NSAID due to the concentrati on of 
cyc looxygenase accumulating in endothelia l cells. Interac ti ons with warfarin can cause serious bleed ing. 2 
In renal function, pro tag landins are important for increasing g lomerular filtration rate, decreasing renal 
va cular resi lance, increasing natriuresi and reducing water reab orpti on in the loop of Henle. Prostag landins may 
also prevent antidi rue tic hormone acti on on tubul ar epithe lium through nega ti ve feedback, to increase water 
eliminati on. However, N AID inhibit pros tag landin synthesis, thus a ll wing exces ive water retention and edema 
formation. The side effec t of edema, fluid and electro lyte di turbances, odium and chloride re tenti on, and pl asma 
dilution can be dangerou .2 
O ther side effec ts of NSAIDs related to cyclooxygenase inhibition include ac ute rhiniti s, urt icari a, 
bronchocon tricti on and hypoten ion in patient · utTering from asthma, chronic obstruc ti ve pulmonary di sea e o r 
other lung ailment . Finally, adver e effec ts that are like ly unre lated to cyclooxygenase inhibiti on can affect a ll body 
sy te rns, ranging from headache, dizzines and rash to myalgia, tinnitus and tl atul ence.2 
The long-term prescription of NSAIDs (non- teroida l anti -inflammatory drug ) to treat osteoarthr iti s for 
patients with a hi tory of peptic ulcer may cause recurrence o f peptic ulcer, due to gastric irritation.3 Non-drug 
therapy, or acetaminophen, or NSAID with gastroprotec ti ve agent is reconm1ended instead . In patient with chronic 
renal failure, NSAIDs may worsen renal failure, causing alt and water re tenti on. Again, non-drug therapy, fo ll owed 
by acetaminophen as necessary, i recor1m1ended as an alternati ve. In pati ent already receiving warfarin , NSAIDs 
may cause increa ed bleeding. In patients with a hi tory of hypertension, NSAIDs may cause salt and water 
retention and exacerbation of hypertension. Thus, acetarrunophen is preferable .4 
Anticholinergic Drugs 
Anticholinergics (muscarinic bl ockers) can be used to correct the dopamine/acetylcholine imbalance in 
Parkinson' disea e, by lowering the acetylcho line acti vity level. Atropine- like drugs such as benztropine and 
trihexyphenidyl can be used . Howe ver, unplea ant side effect of blurred vision, dry mouth , constipati on, urinary 
re tenti on and ataxia may occur. Thi s is becau e sali vary ecre ti on i impaired , so swallowing al o may become 
difficult. Ga tric secretion is diminished, bronchi al ecretion are suppressed , and sweating is impai red . A uch, 
anticholinergics have not been used as first line agents for Parkin on's disease since the introduction of L-dopa. 5 
Alzheimer' disea e i the fourth largest cause of death in people over the age of 65 , and is the most 
common form of dementi a.6 Cholinesterase inhibitors are conm1onl y used in the treatment of A lzheimer's di sease 
related dementia. Donepezil , galantamine or ri vastigmine are o fte n prescribed .7 While cho linesterase inhibitors have 
not been conclusively shown to reverse or slow down mild cognitive impairment, there are numerou randonu zed 
clinical trials that show that cho line tera e inhibitors slow the progre sion o f Alzheimer 's dementi a. Thi s ha been 
suggested to be due to the role o f mu carinic receptors in ne urotrophic regeneration, and acetylcholine tera e 
inhibitors' role in restoration of nicotine receptor acti vity. It ha also been shown that cho line tera e inhibitor can 
inhibit beta-amylo id plaque formati on by impacting secre ti on o f the amyloid precursor prote in (APP).8 The e drug 
do not stop the proce s of neurodegeneration. Newer trategies o f combating Alzheimer' disea e inc ludes 
memantine, a NMDA-receptor antago ni st that ha been reported to be effec ti ve therapeutica ll y in Alzheimer 's 
di ea e, and may be a better alternati ve. 6 
In contra t, due to its po sible oppositi on of bene fi cial e ffect of cholinestera e inhibitors, anticho lineroic 
medications are notorious for wor ening cogniti ve functi on in su ceptible patie nt . Patients with dementi a and u~ge 
incontinence who nught benefit from both an anticholinergic medicati on and a choline tera e inhi bitor pre ent a 
challenge to the cli~ic i a~ , as it eems that the two drug theore tically work again t one another. While the drug 
combinati on is poss1bl ~, rt can be an 1mperfect means of treatment, but no randonuzed contro l tria ls for such case 
have yet been reported. 
The prescription o~ anticholinergic drug to treat irritable bowe l syndrome for patients with dementi a may 
wor en cognitive and behaviOural func tr on. Instead, nondrug and diet therapy, and a calcium channel blocker to treat 
diarrhea, are recommended . The prescription of anticho linergic drugs to prevent extrapyramidal e ffec ts of 
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antip ychoti c drug may cause agitation, delirum. and impaired cognition. Instead, decreased dosages of 
antipsychoti c drugs or the rea sessment of need for these drugs i recommended .4 
Neuroleptic Drugs (Antipsychotic Drugs) 
Neuroleptics are types of antipsychotic medications. Anti psychoti cs can be u ed to treat psychosis that may 
be encountered in pati ents with evere dementia, depress ion or severe metabolic di turbances from liver failure or 
kidney fa ilure. When given to pati ents, the e drugs produce decrease in bi zarre behaviour, delusions, and 
hallucinations. They al o decrea e anxiety, and promote leepine s or edation. In the early 1950's, Laborit, a 
urgeon in Pari s. noted that various antihistamine drugs such as promethazine had a calmjng effect on postoperati ve 
patients. In 1950, Charpentier synthesized chlorpromazine, a related compound, which reduced both the need for 
surgica l anae the ti c and patients' anxiety. A uch, p ychiatrists began to u e the drug for treating psychosis. 10 
Mo t antip ychoti c act e lecti vely on dopamine receptors, blocking doparrune receptors due to their 
irnilar tructure to the dopamine molecule, such a chlorpromazine (a phenothjazine) and haloperidol (a 
butyrophenone). Antip ychoti c ac tion seems to be more c lo e ly linked to D2 than to Dl anatagonism. 
Antip ychoti c can a l o block the actjons of L-dopa, apomorphine, and bromocriptine, whjch are all dopamine 
agonj t . In addition, the chemoreceptor tri gger zone outside of the blood-brajn barrier in the reti cular formation of 
the medulla oblongata, whjch stimulates nausea and vorruting, i ri ch in 0 2 receptor . Thus, antipsychoti cs a lso have 
an effect of reducing nausea. As such, antipsychotics can reduce nau ea produced by o ther drugs , pregnancy, 
radiation sickness, and cancer. 10 
Most side effects of antipsychotics ari se from their cholinergic, adrenergic and histarrunergic receptor 
acti ons, becau e their antipsychotic effects originate from their antidopaminergic ac tions. Peripheral side effect 
include hypotension, constipation and tachycardia.10 Other side effects inc lude antipsychotic-induced parkinsonism 
from effec t on the nigrosti atal pathways, dyskinesia and dystonias, and akathi ia, and later tardi ve dyskinesia over 
month or year . In a study of 56 older psychi atri c patjents, even after controlling for pontaneous extrapyramidal 
sign at ba e line and for natural fluctuations, there was a substantial risk of neuroleptic-induced parki nsoni sm in 
patients treated with very low doses of neuroleptics. 11 In another group of over 3500 pati ents aged 65 to 99 enrolled 
in a Med icaid program in Massachusettes, pati ents were found to be 5.4 time more likely to require 
antiparkinsonian medication if they were taking neuroleptics, a compared to non-users. Neuroleptic use is well-
known and common cau e of ex trapyramidal dysfunc tion in the e lderl y. 12 
Neuroleptic malignant syndrome is a rare but severe ide effect, wruch include extreme rigidity, fever , 
marked autonomic disturbances and muscle destruction. Unwanted edation can be due to a complex interacti on of 
anti_hi tarru nergic , antiadrenergic and anticholinergic actions. Orthostatic hypoten ion occur because antip ychotics 
depre blood pres ure by dilating the arterioles through directl y acting on alpha-adrenoceptors respon ibl e for 
vasoconstriction . There may also be a direct effect on the vasomotor centre, contributing further to hypotension. 
Anticholinergic effects can lead to mydri a is and weakened c iliary muscle , cau ing mydriasis. Decreased tear 
secretion can lead to dry eyes, and mydri asis may decrease aqueou humor outflow and precipitate glaucoma in 
certaj n pati ent . Dry mouth , con tipation, and urinary he itancy may a l o result from anticholinergic e ffects. 
Pseudopregnancy, due to dopamine' s action on the pituitary to inhibit mammotroph ce ll pro lactin re lease, and 
blockage of follicle s timul ating hormone and luteiniz ing hormone may lead to anovul ation, lack of menstruation and 
hyperpro lactinemja, swollen breasts and galactOIThea . ln pati ent pred i posed to seizure , antipsychotic can 
produce eizures , mo t promjnently with low-potency agent . More rare ly, phenothiazine- induced jaundice and 
dermatiti s and photosensiti vity may occur with antipsychotics. 10 
The pre cripti on of chlorpromazine to treat p ycho i for pati ent with a history of postural hypotension 
may wor en po tural hypotension and cau e falls . Alternatively, hi gh-potency neuro leptic such as haloperidol with 
blood pre sure monitoring is recommended.4 
Benzodiazepines 
Chl ordiazepox ide was the first benzodiazepine marketed in 1960, followed by diazepam in 1963 and 
oxazepam in 1965. All benzodiazepines are variation upon the 5-aryi- J ,4-benzodiazepine nucleus. Diazepam and 
many other benz di azep ines are metaboli zed to the active metabolite N-de methyldiazepam, also known a 
nordiazepam. In 1977, specific receptors for benzodi azepines were di covered in the nervous ystem. Type I 
receptors are abundant in the cerebellum, cerebral corti cal layer IV , and the sub tantia nigra. In contrast, Type II 
receptor are located in the hippocampus, superior colliculu and cerebra l corti ca l layers I-III. It is be lieved tha t both 
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anxio lytic and sedative effec ts are medi ated through the Type I receptor , wheras anticonvulsant and muscle 
relaxati on effects are med iated through the Type II receptors. The benzod iazepine receptor may also be lin ked 
cooperatively with GABA receptor , since GABA and GABA agoni sts have been shown to enhance be nzodiazepi ne 
receptor binding abilitie . 13 
Benzodi azepines have an antianxie ty ac ti on. Mo t benzod iazepine have been approved for use in acute 
anxiety di order . Since effi cacy decrea es a bit after a few weeks, the drugs are less use ful in the treatme nt of 
chronic anxiety. Be nzodiazepines also have anticonvulsant ac ti vity, but to lerance to the an ticonvulsant effec t can 
develop with long-term use. Most benzodiazepine are useful in alcohol withdrawal syndrome treatment. 
Benzodiazepines are also use ful for thei r muscle re laxant effects, uch as in treating neurom uscular disorder li ke 
cerebral palsy and te tanus. Furthermore, benzod iazepines are useful for achiev ing amnesia with sedati on. Fi nall y, 
benzodiazepine can treat the ymptom of in omnia. Since elderl y patient are more sensiti ve to the effects of such 
drug , initial dose in patients over age 60 hould be 50% of the li sted dose requirements for insomnia. The most 
common ide effect i a feeling of sedation or mental " fuzziness" in the morning. Patient must at o be reminded 
that no hypnotic drugs should be taken with alcohol , which can be a fatal combinati on. 13 
Common side effec ts of drow ines , atax ia, le thargy and rarely coma occur in les than 10% of ho pitalized 
patient that receive oral benzodiazepine . 13 Delirium, oversedation, and hypoten ion are other major side effects. 
Lorazepam ha been found to be associated with the more seri ous side effects of ataxia and delirium, which could 
re ult in potentiall y debilitating acc idents, inc luding fall and fractures. 14 Other side effect inc lude: interference 
with memory and reca ll , and anterograde amnesia. With intravenous administration of benzodiazepines, important 
but uncommon side effects inc lude: respiratory or cardiac arre t, hypotension, and phlebiti s at the inject ion site . 13 
The long-term prescription of long half-life benzodiazepines to treat insomnia or anxiety may cau e fa lls, 
fracture , confusion, dependence and withdrawal. Alternative inc lude non-drug therapy or the usage of hort half-
life benzodiazepine . Similarly, the long- term prescripti on of a long half-life benzodi azepine to treat agi tation in 
dementia may be replaced by loxapine or haloperidol, or a hort half-life benzodi azepine. 4 
Summary 
Overall , NSAIDs, anticholinergics, neuroleptics and benzodiazepines have both important and eriou side 
effect that are more pronounced in the elderl y. Based on the susceptibility of older patients to adverse events from 
pharmacologic effect , careful consideration of the advantage and di advantage of these medicati ons remains 
valuable. Before prescribing these medications, it is useful for clinician to fir t consider safer alternatives for their 
elderly patient . 
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INSURANCE SOLUTIONS 
at every stage of your 
professional career 
• Life Insurance (~100,000 free for students) 
• Disability Income Plan (special offers for students and residents) 
• Critical Illness Insurance 
• Home and Auto Insurance 
A Membership Benefit of: 
Vi1it our website for deta1ls 
www.OMAinsurance.com u or coli us ot 1-800-758-1641 
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One Vision ... Four Sites 
With the opening of the new Emergency department (January 2007) and the 
opening of the Durham Regional Cancer Centre (May 2007), this is an exciting 
time to join Lakeridge Health, one of the larger hospital networks in Ontario, 
located 45 minutes east of Toronto, in beautiful Durham Region. Through our 
four hospital sites and multiple satellite offices located in both rural and urban 
settings, we offer a broad range of healthcare services. 
In today's dynamic work environment, our dedicated healthcare professionals 
and supporting team use our Better Together approach to provide excellence in 
patient care and service. This is enhanced by our dedication to Health Services 
Training and Research, through the Academic Liaison program and the newly 
created Lakeridge Health Services Institute for Training Education and Research. 
As well, nearby universities and colleges, including the newly created university 
centre- the University of Ontario Institute of Technology, and Durham College, 
offer excellent lifelong learning opportunities. 
For more information on Physician opportunities please contact: 
BOWMANVILLE 
Dr. Murray Treloar, Chief of Staff 
Lakeridge Health Corporation 
(905) 576-8711, ext. 3720 
mdcv@lakeridgehealth.on.ca 
www.lakeridgehealth.on.ca 
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